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Scutellaria baicalensis is a commonly used herb in Traditional Chinese Medicine to treat 
diabetes and its complications owing to its potent antioxidant and radical scavenging activities. 
Many of the diabetic micro- and macrovascular complications are known to arise due to free 
radical-induced oxidative stress and reduced intrinsic antioxidant defenses. Thus, the preliminary 
research work involved the characterization of antioxidant mechanisms of Scutellaria baicalensis 
in type 1 diabetic Wistar rat models. Its bioactive flavonoid compounds were screened for radical 
scavenging potential in an in vitro cell culture model of hyperglycemia. Thereby, baicalin was 
identified as the primary bioactive compound in the herbal extract. The antioxidant potential of 
baicalin was further characterized in the STZ-induced diabetic Wistar rat model. The results 
obtained from this study confirmed baicalin as the primary bioactive compound in Scutellaria 
baicalensis in comparing and contrasting the data with the preliminary in vivo study. It was 
observed that baicalin increased the antioxidant enzyme expression as well as reduced the 
oxidative damage to the intracellular mitochondria. The antioxidant effects of baicalin were also 
investigated in the type 2 diabetic Goto-Kakizaki rat model. The mechanisms of action were 
similar to both animal models. In summary, the identification of baicalin as a potential 
complementary therapeutic agent for diabetes to improve the anti-oxidant status and reduce 
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 According to the statistics of the World Health Organization (WHO), it has been 
estimated that the world prevalence of diabetes will more than double by 2030 (WHO, 2005). 
Although the incidence rates of type 1 Diabetes Mellitus (DM) has remained fairly stable, the 
number of people diagnosed with type 2 DM has been steadily growing. Type 2 diabetes 
currently comprises ~90% of all diabetes cases in both the United States and Europe, and close 
to 100% in Asia (American Diabetic Association, 2003). DM is believed to be a gateway for 
numerous pathologies, including atherosclerosis, coronary heart disease, kidney and liver failure. 
Although modified diet and exercise plans can be effective for reducing obesity and the 
immediate risk of contracting diabetic complications, compliance with such regimens tends to be 
low, which increases the demand for effective pharmacological therapies (Gershell, 2005). 
 Although there are a number of oral anti-hyperglycemic drugs on the market to treat 
diabetes, at present no single marketed drug is capable of lowering glycosylated hemoglobin 
(HbA1c) to the target range for a sustained period of time for the majority of patients with DM 
(Unger, 2008). Even when used in combination, these medications tend to lose much of their 
efficacy after 3 - 4 years of treatment (Dixon et al., 2008). Weight gain is particularly 
troublesome for many of the marketed therapies, and can be induced by current medications such 
as sulphonylureas, α-glucosidase inhibitors and thiazolidinediones; because many with type 2 
DM are already obese, this is a very undesirable side effect (Opar, 2008). When patients with 
type 2 diabetes reach the point at which oral therapies can no longer adequately control their 
blood sugar, the only remaining option is injectable insulin therapy, which is comparatively an 
equal or more failure than the oral anti-hyperglycemic therapies (Gershell, 2005). There is 
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therefore still a need for new agents with novel mechanisms of action to provide both enhanced 
benefit and more favourable side-effect profiles. 
 Emerging evidence is in favour of the concept that oxidative stress plays an important 
role in the development and progression of insulin resistance (Wild, 2004). The vascular 
complications of diabetes are conventionally divided into macrovascular and microvascular 
categories. The most common microvascular complications are retinopathy, neuropathy, and 
nephropathy which are important causes of morbidity and mortality in diabetes patients and have 
been shown to have a direct involvement with oxidative stress. The most common macrovascular 
diabetic complication is cardiovascular disease. There are several studies demonstrating that 
patients with diabetes not only have increased levels of circulating markers of free radical-
induced damage, but also have reduced antioxidant defenses (Brown et al., 2003). 
Hyperglycemia is known to induce oxidative stress via several mechanisms which are linked 
with reactive oxygen species production (ROS). These include glucose oxidation, the formation 
of advanced glycation end-products (AGE), and activation of the polyol pathway (Brownlee, 
2001). These mechanisms would be discussed in detail in the Chapter 2. Other circulating factors 
which are elevated in diabetics, such as free fatty acids and leptin, also contribute to increased 
ROS generation. ROS are considered to be a link between elevated glucose and the other 
metabolic abnormalities important in the development of diabetic complications, and 
normalizing mitochondrial ROS is shown to prevent glucose induced metabolic abnormalities 
that are postulated in the pathogenesis of diabetic complications (Brownlee, 2005).  
 In response to excess ROS production during respiration and metabolism, mammals have 
evolved numerous antioxidant systems including free radical scavengers and enzymes. The first 
and perhaps most important of these antioxidant enzymes is superoxide dismutase (SOD), which 
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exists in three major cellular forms: copper-zinc (CuZnSOD / SOD1), manganese (MnSOD / 
SOD2), and extracellular (SOD3). These enzymes are responsible for the detoxification of 
superoxide radicals to hydrogen peroxide and water in different cellular compartments. 
Glutathione peroxidase (GPx) and catalase (CAT) are other antioxidant enzymes that catalyze 
the conversion of hydrogen peroxide to water. Decreases in expression, and in some instances 
the inactivity of each of these antioxidant enzymes, has been reported in the disease pathologies 
of diabetic microvascular complications (Davies, 2000). This might be especially true for the 
pancreas, since it has a relatively weak intrinsic defense system against oxidative stress.  
 Dietary phenolic antioxidants have been hypothesized to have a protective effect against 
the development of diabetes by inhibiting lipid peroxidation chain reactions which causes 
diabetic complications (Davies, 2000). Flavonoids found in fruits, vegetables and plant-derived 
beverages are known to possess diverse pharmacological actions in the ROS producing chain 
reactions (Halliwell, 2000). There has been considerable interest recently in dietary strategies to 
combat oxidative stress-related damage via the introduction of antioxidants into the diet. 
Phenolic antioxidants in the diet have been shown to be remarkably effective in delaying or 
preventing the onset of chronic inflammatory diseases (Finkel, 2000). For example, resveratrol 
from grapes has been shown to have remarkable biological actions which may be effective 
against cardiovascular disease, some forms of cancer, and arthritis (Baur et al., 2006). 
Subsequent research has shown various other phenolic compounds also to be remarkably 
powerful antioxidants and anti-inflammatory agents (Mills et al., 2003) 
 Phenolic antioxidants work in a number of ways to reduce or prevent the development of 
inflammation (Halliwell, 1998). First, they act as antioxidants in the food and in vivo. Phenolics 
can act as free radical scavengers, removing ROS which can be initiators of oxidative stress and 
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chronic inflammation (Halliwell, 1998). In addition, some phenolics act as direct inhibitors of 
lipoxygenase or cyclooxygenases (particularly COX-2) to mediate the inflammatory response 
(Halliwell, 2005). Some of the phenolic compounds influence oxidative stress and inflammation 
at different points in the inflammatory cascade by controlling gene expression of the antioxidant 
enzymes (Kubisch et al., 2006). 
 Many of the herbs used in Traditional Chinese Medicine (TCM) have been known to 
possess antioxidant properties (Ko et al., 2004; Ou et al., 2003). These herbs are also known to 
be one of the primary sources of novel bioactive flavonoid compounds which are currently in 
trial for combating many oxidative stress-related diseases such as diabetes, cancer, arthritis, and 
Alzheimer’s and Parkinson’s diseases (Schinella et al., 2002). Thus, this research was designed 
to identify, characterize and investigate the antioxidant and anti-diabetic properties of herbs used 
in TCM in in vivo models of diabetes and identify potential bioactive compounds which may be 




 The overall objective of this thesis was to investigate the antioxidant and anti-diabetic 
properties of Scutellaria baicalensis and its primary bioactive compounds for the treatment of 
diabetes in in vivo models of diabetes. The specific objectives were: 
(1) Characterization of the antioxidant and anti-diabetic properties of Scutellaria baicalensis 
in streptozotocin-induced diabetic Wistar rats (Chapter 3) 
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(2) Portrayal of baicalin (the primary bioactive compound extracted from S. baicalensis) as 
the principal source of antioxidant and anti-diabetic activities in the S. baicalensis herbal 
extract in streptozotocin-induced diabetic Wistar rats (Chapter 4) 
(3) Investigation of the effects of baicalin on reducing mitochondria-induced oxidative 
damage (Chapter 5) 
(4) Characterization of the antioxidant and anti-diabetic properties of baicalin in type 2 
diabetic Goto-Kakizaki rat model (Chapter 6) 
(5) Characterization of the antioxidant and anti-diabetic properties of Rehmannia glutinosa 
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2.1 A BRIEF HISTORY OF DIABETES MELLITUS  
 Diabetes is a disease which has been recognized since antiquity especially in the regions 
of Asia and the Mediterranean. However, the elucidation of the pathogenesis of diabetes 
occurred mainly in the 20th century.  
 The role of the pancreas in the disease pathogenesis of diabetes was discovered in 1889 
by Joseph Von Mering and Oskar Minkowski. These two scientists removed the pancreas of 
dogs only to observe the development of diabetic symptoms. However, the endocrine role of the 
pancreas in metabolism and the existence of insulin were not fully clarified until 1921. Sir 
Frederick Grant Banting and Charles Herbert Best repeated the work of Von Mering and 
Minkowski but went a step further to show the reversal of diabetic symptoms in the dogs by 
giving them an extract from the pancreatic islets of Langerhans of healthy dogs.  
 The research by Banting and Best progressed on to the isolation of insulin from bovine 
pancreases at the University of Toronto in Canada. This led to the availability of the first 
effective treatment versus diabetes - insulin injections - and the first clinical patient was treated 
in 1922. For this discovery, Banting et al received the Nobel Prize for Medicine in 1923 followed 
by Banting receiving knighthood in 1934. 








Table 2.1 Milestones and important years in the history of diabetes 
Year Discoverers / 
Journal / Scientists 
Nationality Discovery 
1000 BC Chapter in the 
‘Sāmaveda’ 
India 




30 AD Aretaeus Greek 
The ‘sweetness’ in 
urine and its 
excessive excretion, 
followed by 
emaciation of limbs 
1889 Joseph Von Mering 
and Oskar Minkowski 
Germany Highlighting the 
importance of the 
pancreas in the 
disease pathology of 
diabetes 
1921 Sir Frederick Grant 
Banting and Charles 
Herbert Best 
Canada Discovery and the 
isolation of insulin 
for the treatment of 
diabetes 
1935 Sir Harold Percival 
Himsworth 
UK The distinction 
between type 1 and 
type 2 diabetes 
1942 Marcel Janbon et al France Discovery of 
sulfonylureas (the 1st 
non-insulin therapy 
for diabetes) 




1988 Gerald Reaven USA Identification of the 
metabolic syndrome / 
‘Reaven’s syndrome’ 







Inadequacy of current 
diabetic treatments 




2003 N. J. Wald and M. R. 
Law 
UK Introduction of the 




2004 Michael Brownlee USA The causal link of 




2.2 THE CAUSES OF DIABETES MELLITUS AND ITS COMPLICATIONS 
 
2.2.1 Impaired production of insulin, insulin insensitivity and hyperglycemia 
 As described before in brief, both categories of DM results when pancreatic β-cells are 
unable to maintain adequate insulin secretion to prevent hyperglycemia. A combination of 
genetic and environmental factors causes the underlying β-cell failure. In type 1 DM, a T-cell–
mediated autoimmune response against β-cells appears to be the main disease mechanism, 
whereas insulin resistance is the key metabolic abnormality in type 2 DM (Opar, 2008). Yet, the 
manner in which insulin resistance triggers β-cell failure remains obscure. For many years, 
attempts to distinguish different types of diabetes have been associated with changing definitions 
which reflect the variations in the state of derived knowledge. Terms have changed from juvenile 
and adult diabetes to insulin-dependent and non-insulin-dependent diabetes and finally to type 1 
and type 2 diabetes (Unger, 2008). In addition, there are several intermediate forms, such as 
latent autoimmune diabetes in adults, or ‘type 1.5’ (Wild, 2004). 
 The complications are the primary causes of mortality and morbidity in all forms of 
diabetes. Although the pathogenesis of the diabetes categories differs from each other, the 
pathophysiology of their micro- and macrovascular complications remains similar. Two 
landmark clinical studies - The Diabetes Control and Complications Trial (DCCT) and the 
United Kingdom Prospective Diabetes Study (UKPDS), established that hyperglycemia is the 
initiating cause of the diabetic tissue damage as observed clinically (DCTT, 2007; DCTT, 2000; 
UKPDS, 1998). These processes however, are yet again affected by both genetic determinants of 
individual susceptibility and by independent accelerating factors such as hypertension. Diabetic 
complications may be categorized as macro- and microvascular. The most common 
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microvascular complications include retinopathy, neuropathy and nephropathy (Cnop et al., 
2005; Hovind et al., 2005; Eizirik and Mandrup-Poulsen, 2001) while elevated levels of blood 
pressure, atherosclerosis, coronary heart disease and cerebrovascular disease are examples of 
macrovascular complications (Nordwall et al., 2004; Uusiputa et al., 2003). Thus, researchers 
deemed it worthy of investigating the processes which are modulated by intracellular 
hyperglycemia in cells resulting in the aforementioned complications. 
 
2.2.2 Biochemical mechanisms leading to DM complications 
 It was discovered that a consistent feature common to all cell types damaged by 
hyperglycemia was an increased production of ROS (Brownlee, 2005; Brownlee, 2001). 
Although hyperglycemia had been associated with oxidative stress even as early as the 1960s, 
neither the underlying mechanism nor its consequences for pathways of hyperglycemic damage 
were known during that time. 
 Increased production of ROS occurs within the intracellular mitochondria. Mitochondrial 
ROS generation through hyperglycemia is well described by Brownlee (2005). The 
mitochondrial electron transportation chain (ETC) consists of four protein complexes (I, II, III 
and IV) as shown in Fig. 2.1. Under normal conditions, electron donors are generated when 
glucose is metabolized through the tricarboxylic acid (TCA) cycle. The chief electron donor is 
Nicotinamide Adenine Dinucleotide (NADH), which gives electrons to complex I. The other 
electron donor generated by the TCA cycle is Flavin Adenine Dinucleotide (FADH2), formed by 
succinate dehydrogenase, which donates electrons to complex II. Electrons from both these 
complexes are passed to coenzyme Q, and from there to complex III - cytochrome-C, followed 
by complex IV, and finally to molecular oxygen, which is reduced to water. The ETC is 
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organized in such a way that the level of Adenosine Tris Phosphate (ATP) can be precisely 
regulated. As electrons are transported across the complexes, some of the energy of those 
electrons is used for pumping protons across the membrane at complexes I, III, and IV. This 
generates a voltage gradient across the mitochondrial membrane. The energy from this voltage 
gradient drives the synthesis of ATP by ATP synthase. Alternatively, uncoupling proteins 





Figure 2.1 Production of superoxide by the ETC in the mitochondria (from Brownlee, 2005) 
 
 In contrast, in diabetic cells, more glucose is being oxidized in the TCA cycle, which in 
turn pushes more electron donors (NADH and FADH2) into the ETC. As a result, the voltage 
gradient across the mitochondrial membrane increases until a critical threshold is reached. At this 
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point, electron transfer inside complex III is blocked, causing the electrons to back up to 
coenzyme Q, which donates the electrons one at a time to molecular oxygen, thereby generating 
superoxide. The mitochondrial isoform of the enzyme SOD degrades this oxygen free radical to 
hydrogen peroxide, which is then converted to H2O and O2 by other enzymes. 
 Production of ROS leads to the activation of the following pathways (Fig 2.2):  
1. The polyol pathway (Sheetz and King, 2007; Lee and Chung, 1999) 
2. Protein kinase-C (PKC) pathway (Bishara et al., 2002; Koya et al., 2000) 
3. Advanced Glycation End (AGE)-products synthesis (Dixon et al., 2008; Obrosova et al., 
2004) 
4. The hexosamine pathway (Tesfaye et al., 2005; Clark et al., 2003; Du et al., 2000) 
 
The polyol pathway, shown schematically in Fig 2.2, focuses on the enzyme aldose 
reductase. Aldose reductase normally has the function of reducing toxic aldehydes in the cell to 
inactive alcohols. Under high intracellular glucose concentrations, aldose reductase reduces 
glucose into sorbitol as well (which is subsequently oxidized to fructose). In the process of 
reducing high intracellular glucose to sorbitol, the aldose reductase consumes the cofactor 
NADPH. However, NADPH is also the essential cofactor for regenerating a critical intracellular 
antioxidant, reduced glutathione (GSH). Thereby, the polyol pathway increases susceptibility to 
intracellular oxidative stress (Sheetz and King, 2007; Lee and Chung, 1999). 
Hyperglycemia inside the cell increases the synthesis of diacylglycerol, which is a critical 
activating cofactor for the classic isoforms of PKC – β, δ and α. When PKC is activated by 
intracellular hyperglycemia, it has a variety of effects on gene expression. One aspect of this 
modulation is in the incidence of vasodilator producing endothelial nitric oxide (NO) synthase 
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(eNOS) where its production is decreased, while the vasoconstrictor endothelin-1 is increased 
(Koya et al., 2000). Many in vivo studies have indicated that the inhibition of PKC prevented 




Figure 2.2 Activation of the four pathways leading to diabetic complications through 
mitochondria superoxide production (Brownlee, 2005). 
 
 In considering the third mechanism of ROS induced-tissue damage, AGE precursors can 
diffuse out of the cell and modify extracellular matrix molecules nearby which changes signaling 
between the matrix and the cell and causes cellular dysfunction (Dixon et al., 2008). Many in 
vivo studies indicated the pharmacological prevention of the precursors of AGE-products to 
result in the reduced incidence of diabetes retinopathy (Obrosova et al., 2004).  
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 In the activation of the hexosamine pathway, most of the intracellular glucose is 
metabolized through glycolysis, where glucose is initially converted to glucose-6 phosphate, 
followed by fructose-6 phosphate (F-6-P), and then onto through the rest of the products of the 
glycolytic pathway. However, under hyperglycemic conditions, some of the F-6-P gets diverted 
into a signaling pathway in which the enzyme glutamine: fructose-6 phosphate amidotransferase 
(GFAT) converts the fructose-6 phosphate to glucosamine-6 phosphate and finally to uridine 
diphosphate (UDP) N-acetyl glucosamine (Clark et al., 2003). N-acetyl glucosamine has a 
selective affinity towards serine and threonine residues of transcription factors which often 
results in pathologic changes in gene expression (Tesfaye et al., 2005; Du et al., 2000). Increased 
modification of the transcription factor Sp1 results in increased expression of transforming 
growth factor-1 and plasminogen activator inhibitor-1, cause adverse vascular effects (Du et al., 
2000). 
 
2.3 THE ISSUES ON CURRENT TREATMENTS FOR DIABETES MELLITUS  
 
 Existing treatments of diabetes are focused on improving mechanisms of controlling and 
lowering blood glucose to a normal level which may be summarized as follows: 
1. Stimulation of β-cells of pancreatic islets to release insulin 
2. Increase resistance to the hormones which increases blood glucose 
3. Increase the number insulin receptor sites  
4. Decrease the leaking-out of glycogen 
5. Enhancement of the use of glucose in tissues and organs 
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Based on the mechanisms stated above, the oral anti-diabetic treatments could be classified as 
per Table 2.2. It is necessary to bring into attention that the effect of these drugs is only aimed at 
lowering the level of blood glucose. 
 
Table 2.2 Classification of existing oral anti-diabetic treatments (Das and Chakrabarthi, 2005) 
Mechanism of action Categories of medicines 
Sulfonylureas  (Tolbutamide (D860, 
Orinase), Glibenclamide (Glyburide, 
HB419, Micronase, Daonil), Gliclazide 
(Diamicron), Glibenese (Minidiab), 
Glurenorm (Gliquidone), Glutril 
(Glibornuride) and Glimepiride) 
Insulin secretagogues 
Meglitinides 
Glucose absorption / α-glucosidase - 
inhibitors 
Glucobay (Acarbose), Voglibose, Miglitol, 
Emiglitate, Glyset, Precose 
Reducing, hepatic glucose output (WGO) 
through inhibition of gluconeogenesis and 
to a lesser extent, enhancing insulin 
sensitivity in hepatic and peripheral tissues. 
Biguanides  Phenformin 
(Phenethyldiguanidi Hydrochloridum, 
Diabenide, DBI), Dimethylbiguanide 
(FluamineMetformin, Diaformin, Diabex, 
Mellitin, Obin, Melbine, Metformin, 
Hydrochloride, Glucophage, DMBG) 
Insulin sensitizers Troglitazone, Rosigitazone, Pioglitazone, 
Englitazone 
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2.3.1. Inadequacy of current anti-diabetic remedies in the prevention of diabetic 
complications 
 Despite the mechanisms of action of these treatments, conflicting clinical trial findings 
announced through news releases and press conferences have raised attention about the possible 
dangers of the singular lowering of blood glucose. The Action to Control Cardiovascular Risk in 
Diabetes (ACCORD) trial was precisely designed to test this hypothesis (Nathan et al., 2008; 
Patel et al., 2008). In this study, all patients were randomized to receive either intensive therapy 
with a target HbA1c level of 6.0% or standard therapy with a target level of 7.0% to 7.9%. The 
primary outcome was a composite of myocardial infarction, stroke, or cardiovascular death. 
Standard therapy and especially intensive treatment required the use of multiple agents, which 
included metformin, glimepiride, repaglinide, rosiglitazone, acarbose, exenatide, and insulin. 
These drugs, which all reduce serum glucose levels, were used at the discretion of the 
investigators and the patients. The primary hypothesis or model was that among patients with 
type 2 DM, glucose control as assessed by HbA1c level, regardless of the specific drug, would 
reduce the risk of cardiovascular events. The fact that the trial was stopped 18 months early due 
to an increase in total mortality associated with intensive therapy raises questions about the drug 
therapies. 
 
2.3.2 Suggestion of a ‘polypill’ in the prevention of the development of diabetic 
complications 
 Recently, as a way of overcoming diabetic complications, some observers have been 
advocating the concept of a ‘polypill’ - a single pill that would include the properties of a 
number of key drugs (Grundy, 2006). The proposed combination pill consists of aspirin, an 
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angiotensin converting enzyme (ACE)-inhibitor, a beta-blocker, a statin, a diuretic, and folic 
acid. Since there is no trial evidence to suggest a benefit from the addition of folic acid or a 
diuretic to a regimen for preventing diabetic complications that already includes two blood-
pressure - lowering drugs, others have suggested combinations of four to five drugs that may be 
customized separately for primary prevention of diabetes induced inflammation and tissue 
damage, secondary prevention of coronary heart disease, and secondary prevention of stroke 
(Reddy, 2004). In the area of primary prevention, however, the value of such a pill would have to 
be clearly demonstrated, rather than simply assumed. 
 
2.3.3 Novel therapeutic approaches from herbal sources for the treatment of diabetes and 
its complications 
 Many studies have demonstrated the relationship between botany and medicine. It is well 
known that some extracts from traditional medicinal herbs have many pharmacological actions 
and very little cytotoxicity (Mills et al., 2003). The pharmacological actions of flavonoids, 
lignans, alkaloids, bisbenzyls, coumarins and terpenes from plants have been extensively studied. 
(Halliwell, 2000). There has been a considerable amount of interest recently in dietary strategies 
to combat oxidative stress-related damage in various pathophysiological conditions.  
 Phenolic antioxidants, especially flavonoids, in the diet have been shown to be 
remarkably effective in delaying or preventing the onset of chronic inflammatory diseases 
(Finkel, 2000). An example of such a compound would be resveratrol which has caused much 
commotion recently on its positive effects on ageing-related diseases (Baur et al., 2006). 
Subsequent research has shown many other phenolic antioxidants to be remarkably powerful 
antioxidants and anti-inflammatory agents.  
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Figure 2.3 Structure of flavonoids. Dietary flavonoids are diverse and vary according to 
hydroxylation pattern, conjugation between the aromatic rings, glycosidic moieties, and methoxy 
groups. Polymerization of this nuclear structure yields tannins and other complex species 
occurring in red wine, grapes and black tea (Kotsuyak et al., 2001) 
 
 The antioxidant activity of flavonoids and their metabolites in vitro depends upon the 
arrangement of functional groups about their nuclear structure (Halliwell, 1998) (Fig 2.3). The 
past 15 years of structure-activity relationship (SAR) research has generated several consistent 
lines of evidence supporting the role of specific structural components as requisites for radical 
scavenging, metal chelation and antioxidant activity. (Halliwell, 2005; Kotsuyak et al., 2001).  
 The spatial arrangement of substituents is perhaps a greater determinant of antioxidant 
activity than the flavone backbone alone. Consistent with most polyphenolic antioxidants, both 
the configuration and total number of hydroxyl groups substantially influence several 
mechanisms of antioxidant activity. Free radical scavenging capacity is primarily attributed to 
the high reactivity of hydroxyl substituents which participate in the following reaction: 
 
 The chelating properties of flavonoids and tannins also contribute to their antioxidant 
activity (Williamson et al., 2005). By removing or deactivating iron from iron-loaded 
hepatocytes, flavonoids inhibit oxidative damage. The clinical utility of this knowledge is 
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promising in cases of oxidative stress associated with iron overload, which has been 
demonstrated in iron-overloaded rats (Ng et al., 2000). In these animals, supplemental rutin 
resulted in significant reductions of peroxidation in liver microsomes and oxygen radical 
production by phagocytes, while minimal effects were found among animals with normal iron 
status. 
 Flavonoid compounds are able to influence oxidative stress and inflammation at different 
points in the inflammatory cascade, for instance, by controlling gene expression of the 
antioxidant enzymes (Unger, 2008). In addition, new, low-molecular-mass compounds which act 
as SOD or catalase mimetics are also being touted as having the advantage of scavenging ROS 
continuously by acting as catalysts with efficiencies approaching those of the native enzymes 
(Opar, 2008). 
 While the antioxidant properties of flavonoids support a positive role in human nutrition 
and disease prevention, some focus has also been involved on the pro-oxidant activity of these 
compounds in vitro (Yamashita et al., 1999). Concentrated extracts of flavonoid-rich plants such 
as propolis, pine bark, green tea leaves, soy isoflavones and grape seed are widely marketed as 
nutraceuticals, targeting the aging population and individuals with cardiovascular disease, cancer 
and chronic inflammatory conditions (Yoshino et al., 1999). However, their reports of 
mutagenicity related to flavonoid-mediated oxidative damage raise some obvious concerns 
(Halliwell, 2009). 
 Pro-oxidant activity, nevertheless, is known to be directly proportional to the total 
number of hydroxyl groups. In a report by Hanasaki et al. (1994), a series of mono- and 
dihydroxyflavonoids demonstrated no detectable prooxidant activity, while multiple hydroxyl 
groups, especially in the B-ring, significantly increased production of hydroxyl radicals in a 
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Fenton system. The latter compounds included myricetin and gallocatechin, both of which have a 
pyrogallol structure in the B-ring, which has also been reported to promote hydrogen peroxide 
production (Oshima et al., 1998). 
 In summary, SAR among naturally occurring flavonoids offer preliminary insight into the 
impact of these metabolic alterations on various mechanisms of antioxidant activity 
 
2.4 TRADITIONAL CHINESE MEDICINE IN THE PREVENTION OF DIABETES 
MELLITUS-INDUCED OXIDATIVE STRESS AND ITS COMPLICATIONS 
 
 Traditional Chinese Medicine (TCM) utilizes the yin-yang balance in the prevention, 
diagnosis and treatment of diseases and disorders. In the modern context, the consequences of 
yin and yang imbalance is misunderstood or not understood. A few studies have associated the 
yin-yang imbalance with inequalities of the oxidant-antioxidant status (Ko et al., 2004; Ou et al., 
2003). According to TCM theories, diabetes is associated with yin-deficiency. Thus the herbs 
used to treat diabetes in TCM are believed to be yin-nourishing. According to Li et al., (2004) 
there are about 33 of the Chinese traditional medicines most frequently used in Chinese 
traditional prescriptions for the clinical treatment of diabetes and its complications, out of which 
around 13 medicines or natural products are commonly used in diets for the control and / or 
treatment of diabetes and its complications (Table 2.3). In a comparison of Oxygen Radical 
Absorbance Capacity (ORAC) values of yin-tonic and yang-tonic herbs Ou et al (2003) have 
reported some of the yin-nourishing herbs used in diabetes therapy to have a comparable or 
higher ORAC value of vitamin C and E indicating the herbs’ ability to initiate antioxidant 
activity. 
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Table 2.3  Herbs and natural products used in TCM in the treatment of Diabetes (Li et al., 
2004) 
Herbs most frequently used in anti-
diabetic compound recipes 
Natural products commonly used in 
traditional Chinese diets for the control 
and / or treatment of diabetes and its 
complications 
 Fructus coini 
 Fructus ligustri lucidi 
 Fructus Lycii and Cortex lycii 
radicis 
 Fructus mori, Folium mori and 
Cortex mori radicis 
 Fructus schisandrae 
 Gynostemmae herba 
 Herba dendrobii 
 Herba epimedii 
 Radix astragali seu hedysari 
 Radix clematidis 
 Radix ginseng 
 Radix notoginseng 
 Radix ophiopogonis 
 Radix panacis quinquefolii 
 Radix puerariae 
 Radix rehmanniae and Radix 
rehmanniae praeparata 
 Radix salviae miltiorrhizae 
 Radix trichosanthis 
 Rhizoma alismatis 
 Rhizoma anemarrhenae 
 Rhizoma atractylodis 
 Rhizoma coptidis 
 Rhizoma phragmitis 
 Rhizoma polygonati 
 Rhizoma polygonati odorati 
 Scutellaria baicalensis 
 Semen cuscutae 
 Allii cepa bulbus 
 Allii sativi bulbus 
 Cordyceps sinensis 
 Fructus balsampear 
 Ganoderma lucidum seu japonicum 
 Pericarpium granati 
 Radix asparragi officinalis 
 Rhizoma dioscoreae 
 Semen coicis 
 Semen fagopyri cymosi 
 Semen litchi 




Table 2.4 Chemical compounds in TCM medicines with anti-Diabetic activity (Yin and Chen, 2000) 
 





 Triterpenoids – 
Ginsenoside, 
Senticoside 
 Diterpenoids and 
Sesquiterpenoids  - 
Stevioside, Salvin, 
Salvicin and Salvifoli  
 Monoterpenoids - 
Catalpol, 
Rehmannioside A, B, 






























Numerous bioactive compounds have been found in Chinese medicinal plants for 
diabetes (Ko et al., 2004; Yin and Chen, 2000). These compounds include polysaccharides, 
terpenoids, flavonoids, sterols and alkaloids, and some others, some of which have been 
developed as new drugs and used in clinical treatment of diabetes in China (Table 2.4). 
 Thus, it seems plausible that the use of TCM herbs would be a potential method of 
providing antioxidant activities to the oxidative stress-ridden pathophysiological condition of 
diabetes and its complications. Although, many TCM herbs have been identified as potential 
remedies for many ailments based on oxidative stress, only one herb chosen in particular for this 
research based on data pertaining to previous studies. 
 
2.4.1 Scutellaria baicalensis 
 Scutellaria baicalensis Georgi (黄芩 / ‘Huang Qin’) is one of the most widely used yin-
nourishing traditional Chinese herbal medicines (Chen et al., 2001), and is officially listed in the 
Chinese Pharmacopoeia as one of the herbs to be used in the prevention of diabetic 
complications (Fig 2.4). Ou et al (2003) reported the extract of this herb to possess a high ORAC 
value. Its roots have been used for anti-inflammation, anticancer, treating bacterial and viral 
infections of the respiratory and the gastrointestinal tract, cleaning away heat, moistening aridity, 
purging fire, detoxifying toxicosis, reducing the total cholesterol level and decreasing blood 
pressures (Zhao et al., 2006; Ho et al., 2004; Schinella et al., 2002; Gao et al., 2001). Some 
concentrated composite herbal preparations that contain S. baicalensis as a major ingredient in 
their prescriptions are widely used in oriental countries. 
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Figure 2.4 Dried root of Scutellaria baicalensis 
 
 
Figure 2.5 Chemical structures of the primary flavonoid constituents of Scutellaria baicalensis 
(A) baicalin (B) baicalein (C) wogonin 
 
 S. baicalensis contains a variety of flavones, phenylethanoids, amino acids, sterols and 
essential oils. Its dried roots contain over 30 kinds of flavonoids, such as baicalin, baicalein, 
wogonin, wogonin 7-O-glucuronide, oroxylin A, and oroxylin A 7-O-glucuronide (Gao et al., 
2001; Schinella et al., 2002). Baicalin, baicalein, and wogonin are the main active components in 
S. baicalensis (Figure 2.5). Baicalin is the most abundant component, and is known to possess 
anti-allergic, anti-inflammatory, anti-HIV, anti-tumor, antioxidant and free radical scavenging, 
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and anti-SARS coronavirus effects (Lin et al., 2005; Williamson et al., 2005). Baicalein is known 
to show anti-HIV, anti-tumor, antioxidant and free radical scavenging effects (Ng et al., 2000). 
Wogonin is known to contain anti-respiratory syncytial virus, anti-hepatitis B virus, anti-tumor, 
antioxidant and free radical scavenging properties (Gao et al., 2003; Chan et al., 2000). 
 
2.5 IN VIVO MODELS OF DIABETES MELLITUS 
 
 Animal models have been used extensively in diabetes research. Early studies used 
pancreatectomised dogs to characterize the disease pathology and effects of potential remedies 
(Rees and Alcolado, 2005). In the present day, animal experimentation is contentious and subject 
to legal and ethical restrictions which vary throughout the world. Most experiments are carried 
out on rodents, although some studies are still performed on larger animals. Several toxins, 
including streptozotocin and alloxan, induce hyperglycaemia through pancreatic β-cell toxicity in 
rats and mice (von Herrath and Nepom, 2009). Selective inbreeding has produced several strains 
of animal which are considered reasonable models of type 1 DM, type 2 DM and related 
phenotypes such as obesity and insulin resistance. Apart from their use in studying the 
pathogenesis of the disease and its complications, all new treatments for diabetes, including islet 
cell transplantation and preventative strategies, are initially investigated in animals (Ling et al., 
2001). In recent years, molecular biological techniques have produced a large number of new 
animal models for the study of diabetes, including knock-in, generalized knock-out and tissue-
specific knockout mice (Eizirik and Mandrup-Poulsen, 2001). 
 The scope of this research work was carried out on two rat models of type 1 and type 2 
DM. 
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2.5.1 Streptozotocin-induced rodent models of type 1 diabetes mellitus 
 Streptozotocin (STZ) is a nitrosurea derivative isolated from Streptomyces achromogenes 
with broad-spectrum antibiotic and anti-neoplastic activity. It is a powerful alkylating agent that 
has been shown to interfere with glucose transport, glucokinase function and induce multiple 
DNA strand breaks (Jahr et Al., 2002). A single large dose of streptozotocin can produce 
diabetes in rodents, as a result of direct toxic effects on pancreatic β-cells. Alternatively, multiple 
small doses of streptozotocin are also used (e.g. 40 mg/kg on five consecutive days) for the 
induction of diabetes.  
 In certain susceptible rodents STZ induces an insulinopenic diabetes in which immune 
destruction plays a role, as in human type 1 diabetes (Laybutt et al., 2002). Thus, the multiple 
low-dose streptozotocin model has been used extensively to study the immunological pathways 
that lead to insulitis and β-cell death. However, the agent will produce diabetes even in the 
absence of functional T and B cells and, in contrast to many other spontaneous animal models, 
diabetes cannot be reliably transferred to syngenic recipients by the transfer of splenocytes. 
 
2.5.2 Goto-Kakizaki type 2 diabetic rats 
 The Goto-Kakizaki (GK) rat was developed by the selective breeding of Wistar rats with 
the highest blood glucose concentrations over many generations (Goto et al., 1976). The rats 
develop relatively stable hyperglycaemia upon reaching adulthood. Typically, the fasting blood 
glucose is only mildly elevated but rises further when challenged with dietary glucose. Both 
insulin resistance and impaired insulin secretion are present in this rat model of diabetes (Galli et 
al., 1996). At birth, the GK rat has a reduced number of islets (Mrialles and Portha, 2001). 
Inheritance is polygenic and several genome-wide scans have identified putative susceptibility 
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loci on a variety of chromosomes (Gauguier et al., 1996). In common with human type 2 DM, an 




Figure 2.6 Goto-Kakizaki rat model of type 2 DM 
 
 The GK rat, in common with other animal models of diabetes, develops some features 
that can be compared with the complications of diabetes seen in humans. These include renal 
lesions, structural changes in peripheral nerves and abnormalities of the retina (Murakawa et al., 
2002). Research into these phenomena represents another example of how animal 
experimentation opens up areas that could not be easily studied in man (Nitenberg, 2007). For 
example, serial renal or nerve biopsies cannot be ethically performed in human patients and it is 
similarly difficult to measure the concentrations of intraocular growth factors without recourse to 
rodent models. However, there are certainly differences between the complications seen in 
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animal models and humans and debate exists as to whether any currently available animal model 
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CHARACTERIZATION OF THE ANTIOXIDANT AND ANTI-DIABETIC ACTIVITIES 















The research work under this chapter was carried out in STZ-induced diabetic rats to investigate 
the effect of the ethanolic extract of Scutellaria baicalensis, in comparison as well as in 
combination with metformin. Three groups of STZ-induced diabetic rats were given the 
following treatments for 30 days: (1) metformin 500 mg/kg, (2) S. baicalensis 400 mg/kg, (3) 
metformin 500 mg/kg + S. baicalensis extract 400 mg/kg. In addition, vehicle-treated diabetic 
and non-diabetic controls were used in the experiment. The rats treated with S. baicalensis and 
metformin + S. baicalensis had elevated hepatic activities of the antioxidant enzymes – SOD, 
CAT and GPx, compared with the vehicle- (p < 0.05) and metformin-treated (p < 0.05) diabetic 
groups. Plasma and hepatic lipid peroxide concentrations of the herb-treated and herb + 
metformin-treated groups were also significantly reduced (p < 0.05). In addition, the combined 
treatment caused significant elevations of plasma and pancreatic insulin levels and reductions of 
plasma and hepatic triglycerides and total cholesterol. The study thus showed that S. baicalensis 
enhanced the anti-diabetic effect of metformin in STZ-induced diabetic Wistar rats by improving 
the antioxidant status. It also increased pancreatic insulin content as well as improved the lipid 
profile in these rats. 
 









This study was designed to examine the antioxidant effects of S. baicalensis in STZ-
induced diabetic Wistar rats in comparison as well as in combination with metformin – a 
commonly used oral anti-hyperglycemic drug.  
The mechanisms of metformin action have remained obscure, despite multiple pathways 
of action being proposed, including a decrease of hepatic glucose production, an increase of 
peripheral glucose disposal, and a reduction of intestinal glucose absorption (Zhou et al., 2001). 
However, it is well established that metformin-induced glucose lowering does not involve the 
stimulation of insulin. Many suggested pathways have highlighted that metformin activates 5’-
AMP-activated protein kinase (AMPK) in hepatocytes, thereby reducing activity of acetyl-CoA 
carboxylase and lowering expression of a lipogenic transcription factor as well as inhibiting 
hepatic gluconeogenesis (Evans et al., 2005; Lochhead et al., 2000).  
Though epidemiological studies have shown a comparatively lower incidence of side 
effects associated with metformin (DCTT, 2000; Hannon-Fletcher et al., 2000), no reduction in 
diabetic oxidative stress levels has been reported (Bailey and Turner, 2006; Lee and Peuler, 
2001). Studies with metformin in diabetics to date have also not demonstrated the ability to 






3.2 MATERIALS AND METHODS 
 
All chemicals used were of analytical grade and purchased from either Sigma Chemicals 
(Singapore) or BDH Chemicals (BDH Ltd., Poole, UK), unless otherwise specified. 
 
3.2.1 Preparation of S. baicalensis ethanolic herbal extract   
S. baicalensis was purchased from Thye Shan Medical Hall, Singapore. The root (3 kg) 
was blended in a mechanical blender and immersed in 3 L of 80 % ethanol (Merck, Darmstadt, 
Germany) at room temperature while being stirred in an orbital shaker. After 24 hours, the 
remnants were filtered and the extract was kept in a solvent bottle at room temperature (23 0C). 
The extraction of the residue was repeated 3 times. The combined extract was further centrifuged 
at 12,000g for 20 min to remove residual fibres and then concentrated at 60 0C by a rotary 
evaporator to yield a brown powder. The powder was freeze-dried for 7 days and the resulting 
solids were then ground with a mechanical blender. The resulting powder was stored at -20 0C 
and suspended in distilled water before feeding to the animals. The optimum dose of the herbal 
extract to be used in the long term study was determined by an oral glucose tolerance test 
(OGTT) to be 400 mg/kg.  
 
3.2.2 Determination of the total phenolic content and Oxygen Radical Absorbance Capacity 
(ORAC) of the S. baicalensis ethanolic extract  
The total phenolic content and ORAC value of the herbal extract were analyzed 
according to the method by Huang et al. (2002). The freeze-dried ethanolic extract was 
reconstituted in distilled water to a concentration of 0.1 mg/mL before final analysis. 
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3.2.3 High Performance Liquid Chromatography (HPLC) analysis of S. baicalensis 
ethanolic extract   
For the identification of phenolic compounds in the extract, the freeze-dried ethanolic 
extract was reconstituted in distilled water at a concentration of 0.1 mg/mL and filtered through a 
0.45 µm PTFE filter (Schleicher & Schuell, Whatman, Singapore). Analysis was performed 
using a Shimadzu HPLC system with an SIL­10AD auto injector, LC­10AT pump, SCL­10A 
system controller, CTO­10AC Column oven and SPD­M10A Diode Array Detector. The 
analysis was carried out with a Shimadzu VP­ODS C18 column. The mobile phase consisted of 
degassed solutions of Acetonitrile (A) and 0.1 % trifluoroacetic acid in distilled water (B). The 
gradient was as follows: 0 min, 10 % A; 25 min, 43 % A; 30 min 43 % A; 37 min, 10 % A. The 
flow rate was 1 mL/min and the injected sample volume was 20 µL. Peaks were quantified using 
standards and diode array detection at 285 nm.  For the identification of sugars, the freeze-dried 
powder was reconstituted in distilled water at a concentration of 0.5 mg/mL. HPLC was 
performed using a Waters HPLC system with 515 HPLC pump, 2414 Refractive Index detector 
(RI), Column Heater Module and manual injector. The compounds were separated using a 
Waters Sugar Pak I column (6.5 x 300mm, USA), with the column temperature set at 80 °C. The 
detector temperature was set at 50 °C. An isocratic gradient of 100% distilled water was used. 
The flow rate was 0.4 mL/min and the injected sample volume was 20 µL. Minor compounds 
present in the extract were identified and quantified by peak integration by 1H Nuclear Magnetic 




3.2.4 Oral Glucose Tolerance test (OGTT) to determine the optimum dosage of S. 
baicalensis    
Prior to the OGT test, rats were fasted for 12 – 15 hours. Distilled water, metformin (500 
mg/kg) or different doses of the ethanolic extract of S. baicalensis (100, 200 or 400 mg/kg) were 
orally administered to groups of 6 rats. Thirty minutes later, glucose (2 g/kg) was orally 
administered to the rats in each group. Blood samples were collected from the tail vein at -30 
min (before the administration of distilled water, metformin or herb), 0 min (before 
administration of glucose), 60 and 120 min (after glucose administration) for the assay of plasma 
glucose. The percentage change in blood glucose level was assessed in determining the dosage of 
herb for the long-term study. The optimum dosage was determined to be 400 mg/kg (see 
‘Results’ - section 3.3.2). 
 
3.2.5 In vivo study   
The study was carried out as approved by the Institutional Animal Care and Use 
Committee (IACUC), National University of Singapore. Locally bred male Wistar rats weighing 
250 ­ 300 g each were obtained from the Laboratory Animal Center, National University of 
Singapore and housed in a room with a controlled temperature (22 ± 3 0C) on a 12: 12 light/dark 
cycle. Unless otherwise specified, animals had free access to pelleted food containing the AIN-
93M Maintenance Purified Diet (Glen Forrest, WA, Australia) with tap water ad libitum. 
Diabetes was induced in the rats after fasting for 18 hours by intraperitoneal injection of 65 
mg/kg body weight of STZ (Sigma­Aldrich, MO, USA) which was dissolved in citrate buffer 
(0.01 M, pH 4.5) just before use. The diabetic state was assessed by measuring the non-fasting 
serum glucose level 5 days after the administration of STZ. Rats with a serum glucose level 
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above 250 mg/dL as well as polydipsia, polyuria and polyphagia were selected for the 
experiment.  
 The diabetic rats were divided into 4 groups (each n=6) and were administered the 
following treatments through oral gavaging: (1) M - metformin 500 mg/kg, (2) SB - S. 
baicalensis 400 mg/kg, (3) MSB - metformin 500 mg/kg and S. baicalensis 400 mg/kg and (4) D 
- diabetic control. A non-diabetic control (ND) was also used in the experiment. The respective 
treatments were given for 30 days. On the evening of day 30, the rats were fasted overnight and 
euthanized the following morning by decapitation. Blood was collected by drainage from the 
carotids and kept in 200 μL aliquots at ­80 0C till time for assay. The liver, pancreas and kidney 
of the rats were removed, sectioned into 0.5 g aliquots, immersed in liquid nitrogen and stored at 
­80 0C till the time for assay 
 
3.2.6 Determination of enzymatic antioxidant activities and expression 
 Liver samples (0.5g) were homogenized in potassium phosphate buffer (5 mL, 0.05M 
with 0.1 mM EDTA, pH 7.8). The homogenate was centrifuged at 10,000 rpm for 10 min at 4 0C. 
The supernatant was divided into aliquots and kept at -80 0C for the enzyme assays. CAT, SOD, 
and GPx activities were determined using the respective assay kits from Cayman Chemicals, MI, 
USA. Protein expression was analyzed by standard Western blot using the Laemmli SDS-PAGE 
for separation of proteins. Primary antibodies for CAT, SOD and GPx were purchased from 
Santa Cruz Biotechnology Inc., (Santa Cruz, CA, USA). Primary antibody binding was 
visualized by horseradish peroxidase-conjugated secondary antibodies (Santa Cruz 
Biotechmology Inc.) and an enhanced chemiluminescence (ECL) assay kit (Pierce 
Biotechnology, IL, USA). 
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3.2.7 Determination of plasma, hepatic, kidney and pancreatic lipid peroxide contents 
 The lipid peroxide contents were measured as markers of oxidative stress. The 
measurement was carried out according to the method by Hay et al (2007) as described below. 
 Standard curve determination using 13­(S)­HpODE (13­(S)­Hydroperoxy 
Octadecanoic Acid).  A nano CdSe quantum dot (QD) stock solution of 48 nM was 
prepared in hexane and placed in a glass vial. A stock solution of 0.03 µL/mL 13-(S)-HpODE 
and its dilutions were prepared in decane and kept at -20 0C before addition to the QD solution. 
To 2 mL of the QD solution 20 µL of 13-(S)-HpODE dilutions were added and vortexed. The 
mixture was kept in the dark at room temperature for 40 min before the fluorescence 
spectroscopy was read with an excitation wavelength of 400 nm. The logarithmic value of the 
13-(S)-HpODE concentrations versus the logarithmic ratio between the maximum fluorescence 
intensity at 554.5 nm of the blank and the  13-(S)-HpODE samples was plotted as the standard 
curve.  
 Measurement of lipid peroxides in plasma.  To 0.2 mL of plasma sample 0.75 
mL of chloroform and 0.25 mL of methanol were added, vortexed and centrifuged at 5000 rpm 
for 10 min. The lower phase was collected and added with 10 ppm BHT. The plasma lipid 
peroxide sample obtained was further diluted in decane to obtain an 8 times diluted stock 
solution. 20 µL of plasma was added to 2 mL of CdSe QD solution and kept in the dark for 40 
min. The maximum fluorescence intensity was used to obtain the plasma lipid peroxide 
concentration using the 13-(S)-HpODE standard curve. 
 Determination of lipid peroxides in liver, kidney and pancreatic tissues. Liver and 
kidney tissues (0.6 g) were homogenized in a mixture of chloroform and methanol (2:1 ratio by 
volume, 6 mL). The homogenates were centrifuged at 5000 rpm for 15 min and the supernatants 
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were removed. The chloroform layer was isolated using a Pasteur pipette, and the solvent was 
removed using liquid nitrogen. The resulting residue was reconstituted in 6 mL of decane. The 
analysis was carried out as per the steps mentioned above. Pancreatic tissues (0.6 g) were freeze 
dried for 3 days and the resulting residue was homogenized in a mixture of chloroform and 
methanol (2:1 = v:v, 6 mL). The homogenates were centrifuged at 5000 rpm for 15 min and the 
supernatants were removed. The analysis steps were carried out as per the previous section. 
 
3.2.8 Determination of plasma and pancreatic insulin contents 
Plasma and pancreatic insulin concentrations were determined by Enzyme Linked 
Immunosorbent Assay (ELISA) using assay kits provided by Crystal Chemical Inc, IL, USA. 
Prior to analysis, the pancreatic tissues (0.1 g) were disintegrated by ultrasound  in 5 mL of acid-
alcohol solution (75 % ethanol, 1.5 % 12 M HCl, and 23.5 % distilled water) for one min at 4 0C. 
The homogenates were kept overnight at ­20 0C and centrifuged at 1000 rpm for 15 min. 
 
3.2.9 Determination of plasma glucose, triglycerides (TG) and total cholesterol (TC) levels 
Glucose concentrations were measured using the Enzymatic Glucose Reagent (Thermo 
Electron Corporation, Victoria, Australia) by the glucose oxidase method. TC and TG 
concentrations were measured by the colorimetric method using diagnostic kits from Infinity™ 
(Thermo Electron Corporation, Victoria, Australia). Insulin and Leptin concentrations were 





3.2.10 Determination of hepatic TG, TC and lipase activities   
Hepatic TG, TC and lipase activities were measured at the end of the study. For hepatic 
TG and TC analysis, the liver samples (0.5 g) were homogenized with a Polytron homogenizer in 
isopropanol (10 % w/v) at 4 0C for 1 min. The homogenate was centrifuged at 5000 rpm for 15 
min at 4 0C. The supernatants were used to assess the TC and TG contents using the reagent 
assay kits by Thermo Electron Corporation (Victoria, Australia). For assessment of hepatic lipase 
activity, liver samples (0.5 g) were homogenized in ammonium chloride solution (1 mL, 0.025 
M) using a Polytron homogenizer at 4 0C for 1 min. The homogenate was centrifuged at 5000 
rpm for 15 min at 4 0C. The supernatant was freeze-dried for 3 days and the resulting powder 
was reconstituted in an ammonium chloride solution (0.025 M) to a concentration of 10 mg/ml. 
MarkerGene™ Fluorescent Lipase Assay kit (OR, USA) was used to quantify the hepatic lipase 
activity. 
 
3.2.11 Determination of hepatic Glucose-6-Phosphatase (G6Pase) activity  
Hepatic G-6-Pase activity was assayed according to Baginski et al. (1974). Liver samples 
(0.1 g) was homogenized in 5 mL of buffer containing sucrose (0.25 M) and Hepes (5 mM) 
using a Polytron homogenizer and centrifuged at 10,000 rpm at 4 0C for 10 min. The supernatant 
(2 mL) was transferred into ultra-centrifuge tubes and centrifuged at 100,000 rpm in 4 0C for 10 
min. The supernatant was discarded and the pellet was re-suspended in the buffer containing 0.25 
M sucrose and 5 mM Hepes. The standards were prepared using K2HPO4 to final concentrations 
of 0.1, 0.2, 0.3, 0.4 M. Cacodylate buffer (0.1 mL, 100 mM, pH 6.5) and monosodium glucose-
6-phosphate (0.1 mL, 100mM) was added to 0.1 mL each of the sample and standard solutions 
and incubated at room temperature (25 0C) for 10 min. A buffer (2 mL) containing 
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trichloroacetic acid (10 %) and ascorbic acid (2 %) was added to each of the samples and 
standards. The resulting homogenate was centrifuged at 3000 rpm for 10 min. Ammonium 
molybdate (0.5 mL, 1 % in 1 N H2SO4) and a buffer (0.5 mL) containing sodium arsenite (1 %) 
and sodium citrate (1 %) was added to the resulting supernatant. The resulting solution was 
incubated at room temperature (25 0C) for 15 min. The absorbance was read at 840 nm. The 
amount of inorganic phosphate liberated by the enzyme was calculated by comparing the 
absorbance values of the standard. The protein content in the samples was determined by the 
Bio-Rad Protein Assay Reagent (Bio-Rad Laboratories, CA, USA). 
 
3.2.12 Determination of hepatic glycogen content  
The hepatic glycogen content was determined according to the method by Murat and 
Serfaty (1974). Frozen liver tissue (0.1 g) was homogenized in 2 mL of citrate buffer (0.1 M, pH 
4.5) with a polytron homogenizer. The amount of free glucose in the homogenate (10 µl) was 
measured using the glucose analyzer by Thermo Electron Corporation. Amyloglucosidase (1 mg) 
was added to each of the homogenates and kept at room temperature (25 0C) for 2 hours. The 
glycogen content was determined by comparing the amount of glucose liberated from the tissue 
and was expressed as miligram of glucose per gram wet weight of liver tissue. 
 
3.2.13 Determination of plasma leptin, glucagon, C-reactive protein (CRP), Aspartate 
Transaminase (AST) and Alanin Transaminase (ALT) contents    
Plasma Leptin concentrations were determined by ELISA using an assay kit purchased 
from Crystal Chemical Inc, IL, USA. Glucagon Enzyme Immuno Assay (EIA) kit (Cosmo Bio 
Co. Ltd., Tokyo, Japan) was used to determine the plasma glucagon content and the plasma CRP 
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content was measured using the EIA kit by US Biological, MA, USA. AST and ALT activities 
were measured using assays kits provided by Thermo Electron Corporation, Victoria, Australia. 
 
3.2.14 Determination of kidney 8­isoprostane F2α (isoprostane)   
Kidney samples (0.5 g) were homogenized in NaOH (2.5 mL, 2 M) for 1 min at room 
temperature, and incubated at 45 0C for 2 hours in a water bath. Thereafter HCl (2.5 mL, 2 M) 
was added to the homogenate. The neutralized samples were centrifuged at 3000 rpm for 15 min 
and the supernatants were removed and stored at ­20 0C till the analysis was carried out. The 
isoprostane content was determined as per the protocol provided with the Correlate EIA™ assay 
kit (Assay Designs, MI, USA). 
 
3.2.15 Histological analysis 
The rats’ liver, kidney and pancreas were fixed in formaldehyde (4.0 %) for 
approximately 48 hours. Tissue processing was carried out using a Leica TP1020 automated 
tissue processor (Leica Microsystems GmBH, Wetzlar, Germany) followed by paraffin wax 
embedding (Leica EG 1140 C). Upon hardening of the wax, tissue sectioning was performed 
using a Leica RM 2135 rotary microtome. The sections were added onto polylysine slides. 
Following Haemotoxylin and Eosin (H & E) staining, the slides were mounted using DePex 
(Sigma, Singapore) before further observation and analysis. 
 
3.2.16 Statistical analyses  
Results are reported as mean ± standard error of the mean (SEM). Statistical differences 
among groups were calculated by using one-way ANOVA and two-way ANOVA where 
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applicable, using SPSS version 12.0. Results were considered significant when p values 
generated from post-hoc comparisons were <0.05, where applicable. Post-hoc comparisons were 
conducted with Tukey and Bonferroni tests. 
 
3.3 RESULTS  
 
3.3.1 Analysis of the chemical composition of S. baicalensis extract 
The mean total phenolic content in the freeze-dried herbal extract was 52.95 mg gallic 
acid equivalents (GAE) per gram of extract while the mean ORAC value was 1690.1 µmol trolox 
equivalents (TE) per gram of extract. Thus, the optimum dose of 400 mg/kg administered to the 
rats ccontained 21.2 GAE/kg in terms of the phenolic content and 674.0 TE/kg in terms of 
ORAC value.  The total phenolic content and ORAC value of the normal daily feed were 
determined to be 4.9 µg GAE/g and 7.9 µmol TE/g, respectively. These are negligible compared 
with the values of the herbal extract. Metformin did not show any dose-dependent effect in terms 
of the ORAC value, indicating that it does not show any antioxidant activity. 
The HPLC analysis of the phenolic compounds present in the S. baicalensis extract is 
shown in Figure 3.1A. The major component present in the extract was identified as baicalin. 
The extract contained 29.6 % of this compound. Baicalein and wogonin were also present in the 
extract, but in lesser amounts of 1.3% and 0.7% respectively as quantified by 1H NMR analysis. 
The NMR diagrams are shown in Figures 1 – 3 of the appendix. The identification of sugars 
present in the extract is shown in Figure 3.1B. The primary sugar in the extract was sucrose, 




         A                B 
 
 
Figure 3.1 HPLC chromatograms of (A) phenolic compounds  (B) sugars  present in the 
ethanolic extract of S. baicalensis. The major phenolic compound (peak no. 1 in 1A) was 
identified as baicalin which comprised 29.6% of the extract. The peaks on sugar analysis were 
identified as follows: 1. Unknown compound 2. Stachyose 3. Raffinose 4. Sucrose 5. Glucose 6. 
Galactose 
 
3.3.2 Determination of optimum dosage of S. baicalensis for the long-term study 
The dosage of S. baicalensis which had the highest statistically significant (p < 0.05) 
percentage reduction of plasma glucose levels from the OGTT was 400 mg/kg (Figure 3.2). 
Metformin had the highest overall percentage reduction of plasma glucose levels compared with 
the diabetic control (p < 0.05). Therefore, the S. baicalensis dosage of 400 mg/kg was chosen as 




Figure 3.2 Percentage plasma glucose level variations during the OGTT. Values are expressed 
as mean ± SEM (Standard Error Mean). Each group includes 6 rats per treatment. * p < 0.05 
versus the diabetic control; † p < 0.05 versus the metformin-treated group 
 
3.3.3 Effects of the treatments on blood glucose, plasma and pancreatic insulin content  
The plasma blood glucose levels were measured on a weekly basis throughout the 30 
days of treatment. As shown in Figure 3.3A, groups M and MSB showed statistically significant 
reductions of plasma glucose from week 1 onwards and group SB from week 2 onwards 
compared with the diabetic control (p < 0.05).  
The overall mean percentage reductions of blood glucose in the different treatment 
groups at the end of 30 days of treatment in each of the groups were as follows: SB – 40.7%, M 
– 51.8% and MSB – 38.2%. Despite showing the lowest percentage decrease, group MSB had 
the lowest blood glucose level at the end of the 30-day period of treatment, being 184.3 mg/dL 
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compared with 213.9 mg/dL (SB) and 192.6 mg/dL (M). Though these plasma glucose 
concentrations did not reach the levels of the non-diabetic control, the overall trend was towards 
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Figure 3.3 Effects of metformin, S. baicalensis and metformin + S. baicalensis on (A) weekly 
blood glucose levels (B) plasma insulin concentration (C) pancreatic insulin content in STZ-
diabetic Wistar rats. Values are expressed as mean ± SEM. Each group includes 6 rats per 
treatment. * p < 0.05 versus the diabetic control; † p < 0.05 versus the metformin-treated group 
 
The plasma insulin content of MSB (1.21 ± 0.06 ng/ml) was significantly higher than that 
of group M (0.93 ± 0.03 ng/ml) (p < 0.05) indicating an enhancing effect of the combined 
 79
treatment (Figure 3.3B). The enhancement was also observed in the pancreatic insulin content 
(Figure 3.3C) compared with the diabetic control (0.20 ± 0.03 ng/ml, p < 0.05). 
 
3.3.4 Effects of the treatments on CAT, SOD, GPx and GST activities  
An improvement in the antioxidant enzyme activities (compared with the diabetic 





























































































Figure. 3.4 Effects of metformin, S. baicalensis and metformin + S. baicalensis on hepatic (A) 
CAT activity (B) SOD activity (C) GPx activity (D) protein expression of CAT, SOD and GPx 
in STZ-diabetic Wistar rats. The values were measured on day 30 and are representative of 6 rats 
per group. Results are expressed as mean ± SEM. * p < 0.05 versus the diabetic control; † p < 
0.05 versus the metformin-treated group 
D 
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Group MSB showed a significant increase in all the antioxidant enzyme activities 
compared with group M (p < 0.05). As shown in Table 3.1, enzyme activities in group MSB 
relative to the normal controls were more than 50% higher. Western blot analysis of the 
antioxidant enzymes also indicated increased protein expression in groups SB and MSB (Figure 
3.4D).   
Table 3.1 Antioxidant enzyme activities of the treatment groups 
Treatment group  
(each n=6) 
CAT (%)* SOD (%)* GPx (%)* 
Diabetic control (DC) 19.7 21.4 7.3 
Metformin (M) 25.6 43.2 32.7 
S. baicalensis (SB) 40.9 61.4 35.8 
Metformin & S. baicalensis (MSB) 74.2 79.9 79.7 
* The activities are expressed as a percentage of that in the non-diabetic control 
 
3.3.5 Effects of the treatments on lipid peroxide levels in liver, kidney and pancreas  
The plasma lipid peroxides were measured on a weekly basis (Figure 3.5A). A 
significant decrease in plasma lipid peroxide levels was observed in groups M, SB and MSB 
from week 2 onwards, compared with the diabetic control (p < 0.05).  From week 1 onwards, 
group MSB was found to have an enhanced reduction of lipid peroxides (p < 0.05) compared 
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Figure 3.5 Effects of metformin, S. baicalensis and metformin + S. baicalensis on (A) weekly 
plasma lipid peroxide concentrations (B) hepatic lipid peroxide contents (C) kidney lipid 
peroxide contents (D) pancreatic lipid peroxide contents in STZ-diabetic Wistar rats. The lipid 
peroxide contents are expressed as mean ± SEM and represent the analysis of 6 rats per group. * 
p < 0.05 versus the diabetic control; † p < 0.05 versus the metformin-treated group 
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The lipid peroxide contents of the liver, kidney and pancreas were measured at the end of 
the study (Figure 3.5B-D). An enhanced reduction in the hepatic lipid peroxide was observed 
when comparing the concentrations in groups M (73.17 ± 2.44 nM/g) and MSB (52.90 ± 1.09 
nM/g) (p<0.01). However, this decrease was not observed with kidney and pancreatic lipid 
peroxide contents in these two groups although there was a statistically significant reduction in 
lipid peroxide contents in all the treatment groups compared with the diabetic control (p < 0.05).  
 
3.3.6 Effects of the treatments on plasma and hepatic TG and TC contents, and lipase 
activity  
Significant reductions in plasma TG (Figure 3.6A) were observed in groups SB (86.9 ± 
12.6 mg/dl), M (102.4 ± 10.2 mg/dl) and MSB (99.7 ± 3.3 mg/dl) compared with the diabetic 
control (215.7 ± 15.8 mg/dl) (p < 0.05). The reductions in plasma TG in groups S and MSB were 
statistically significant compared with group M (p < 0.05) indicating the hypotriglyceridaemic 
effect of the herbal extract.  
A similar trend was observed in the plasma TC levels. Group M did not show a 
significant reduction in hepatic TC; however, a significant reduction was observed in group MSB 
compared with the diabetic control (p < 0.05). As shown in Figure 3.6B, hepatic TC and TG 















































































Figure 3.6 Effects of metformin, S. baicalensis and metformin + S. baicalensis on (A) plasma 
TG (B) plasma total cholesterol TC (C) hepatic TG (D) hepatic TC in STZ-diabetic Wistar rats. 
Values are expressed as mean ± SEM (Standard Error Mean). Each group includes 6 rats per 
treatment. * p < 0.05 versus the diabetic control; † p < 0.05 versus the metformin-treated group 
 
The results of the hepatic lipase activity are shown in Figure 3.7. Groups M (1.66 ± 0.8 
nmol/min/mg), SB (1.46 ± 0.05 nmol/min/mg) and MSB (1.07 ± 0.08 nmol/min/mg) showed 
significant decreases (p < 0.05) in lipase activity compared with the diabetic control (2.19 ± 0.04 
nmol/min/mg). The lipase activities in groups SB and MSB were significantly reduced (p < 































Figure. 3.7 Effects of the treatments on hepatic lipase activity in STZ-diabetic Wistar rats. The 
enzyme activities are expressed as mean ± SEM and represent the analysis of 6 rats per group. * 
p < 0.05 versus the diabetic control; † p < 0.05 versus the metformin-treated group. 
 
3.3.7 Analysis of organ pathology  
The plasma Aspartate Transaminase (AST) and Alanine Transaminase (ALT) activities 
were measured for detection of possible damage to the liver and kidney tissues (table 1 of the 
appendix). AST activities were significantly reduced (p < 0.05) in groups M (75.68 ± 4.98 U/L), 
SB (70.69 ± 19.13 U/L) and MSB (65.48 ± 14.18 U/L) compared with the diabetic control 
(119.92 ± 17.62 U/L) but were not statistically significantly different from the non-diabetic 
control (70.94 ± 4.71 U/L, p < 0.05). The ALT activity of only group SB (47.85 ± 3.23 U/L) was 
statistically significantly reduced (p < 0.05) compared with the diabetic control (56.56 ± 7.75 
U/L). Despite the varying AST and ALT levels, histochemical analysis of kidney and liver 
tissues did not show evidence of pathological damage (Figures 3.8 and 3.9). 
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Figure 3.8 Histology of the kidney in STZ-diabetic Wistar rats. The images were taken under 
x100 magnification with H & E staining. Observation of the kidney sections did not indicate 
renal pathology in any of the treatment groups. Scale bars indicate 750µm 
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Figure 3.9 Histology of the liver in STZ-diabetic Wistar rats. The images were taken under x100 
magnification with H & E staining. Observation of liver sections did not show any signs of 
hepatic deterioration in any of the treatment groups. Scale bars indicate 750µm. 
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3.3.8 Other bio-markers and hormones   
The values of the other parametes - plasma leptin, C-reactive protein (CRP), Glycogen 
Synthase Kinase (GSK), phosphorylated-GSK (pGSK), glucagon, Glucose-6-Phosphatase (G-6-
Pase), hepatic glycogen and kidney 8­isoprostane F2α (isoprostane), are shown in table 1 of the 
Appendix. These parameters (except plasma glucagon, CRP and isoprostane) were not enhanced 
in the MSB-treated group compared with group M (p>0.05). However, all the treatment groups 
had statistically significant changes as compared with the diabetic control (p < 0.05). 
 
3.4 DISCUSSION 
The key finding in this study was the elevated activity of the antioxidant enzymes 
produced by S. baicalensis in the diabetic rats. Reduction of plasma, hepatic, kidney and 
pancreatic lipid peroxides were an indirect confirmation of the herb’s antioxidant activity. From 
the ORAC, antioxidant enzyme and Western blot data, it may be surmised that the herbal extract 
had initiated antioxidant activity via a two-fold pathway: (1) direct scavenging of free radicals 
and (2) stimulating the expression and activity of antioxidant enzymes. As already well 
established, hyperglycemia leads to the excessive production of ROS which in turn damages the 
tertiary structure of the antioxidant enzymes (Taylor, 2007; Evans et al., 2005). It is likely that 
the radical scavenging activity of the herb reduced the denaturation of the antioxidant enzymes 
caused by the free radicals. Reduction of free radicals as well as increased expression of 
antioxidant enzymes would in turn result in the reduction in lipid peroxide contents in the organs. 
While metformin did not show any radical scavenging activity when analyzed with the ORAC 
assay, it was observed to cause a significant increase in the antioxidant enzyme activities 
compared with the diabetic control. Metformin was also observed to have efficiently reduced the 
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hyperglycemic status compared with the diabetic control. Thus, while metformin may not 
directly scavenge free radicals, the elevations in antioxidant enzymes in group M rats could be 
due to reduced generation of ROS resulting indirectly from reduced hyperglycemia, thus 
ultimately diminishing the oxidative damage to the antioxidant enzymes. 
Metformin was observed to be more efficient in initiating a hypoglycemic effect than S. 
baicalensis. As implied before, reducing the circulating plasma glucose concentrations is one of 
the factors of the equation in the treatment of diabetes since hyperglycemia causes oxidative 
stress which in turn results in long-term complications (DCTT, 2000). However, reduction of 
hyperglycemia alone was seen to be an inefficient mode of therapy in many epidemiological 
studies (Eizirik and Mandroup-Poulsen, 2001). These studies have shown persisting oxidative 
stress-induced endothelial dysfunction even when glycemia is normalized. Thus, metformin (and 
other hyperglycemic agents) when given alone is insufficient to reverse or prevent such 
dysfunctions (Hovind et al., 2005). It appears that direct interventions to reduce oxidative stress 
can play a significant role in the overall therapy of diabetes. 
Although the S. baicalensis and S. baicalensis + metformin treatments had increased the 
antioxidant activity of the rats in groups SB and MSB respectively, the lipid peroxide 
concentrations in these groups were still significantly higher compared with the non-diabetic 
control even after 30 days of treatment. This observation highlights the irreversible alterations in 
physiological oxidant status induced by the pathology of the disease.  
In comparing the antioxidant parameters with the anti-diabetic parameters such as plasma 
glucose levels, the latter parameter of group MSB did not indicate a synergistic or additive effect 
compared with group M in terms of the anti-diabetic activity. Therefore, it is possible that the 
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antioxidant properties of S. baicalensis are not a critical factor in contributing to its anti-diabetic 
effects. 
Another noteworthy observation was the ability of S. baicalensis to reduce plasma and 
hepatic TG and TC contents. Evidence from many areas of research suggests that the ready 
availability of free fatty acids (FFA) for oxidation by muscles and other tissues may lead to 
impairment of carbohydrate oxidation and lead to glucose intolerance as seen in obesity and 
obese diabetics (Buchanan, 2007; Tuomilehto and Wareham, 2006). In addition, FFA can 
stimulate hepatic gluconeogenesis and alter pancreatic insulin release as well as pathways of 
glucose metabolism (Festa et al., 2006). More specifically, increased intracellular TG has been 
hypothesized to be the cause of β-cell dysfunction since TG depletion through caloric restriction, 
administration of troglitazone or leptin had been shown to reverse the diabetes phenotype 
(Reddy, 2007). Therefore, the reduction of circulating TG and TC is an important aspect of the 
treatment of diabetes which was not achieved with metformin in this study. On the other hand, S. 
baicalensis caused significant reductions in hepatic TG and TC contents. 
A significant enhancement in plasma and pancreatic insulin levels was observed in group 
MSB compared with group M. Administration of STZ is known to initiate pancreatic β-cell death 
resulting in an in vivo model for the study of type I diabetes (Garofano et al., 2005). However, a 
few studies have shown the damage by STZ to be partial, leaving some β-cells undamaged 
(Suckow et al., 2006).  
Intact islets of Langerhans were seen in the histological analysis of the pancreas of the 
diabetic rats (Appendix, Figure 4) further confirming that there was only partial destruction of 
pancreatic β-cells by STZ. The STZ-model thus has decreased plasma insulin as well as 
pancreatic insulin contents compared with the non-diabetic control. The plasma insulin 
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concentrations of the treatment groups are still significantly lower than the concentrations of the 
non-diabetic control. The enhanced levels of pancreatic insulin in groups SB and MSB may be 
attributed to the protective effects of free radical scavenging activity by S. baicalensis. Analysis 
of pancreatic pathology was an important aspect of the study to obtain evidence of such 
protection since the pathology of the pancreatic tissues of groups SB and MSB were better than 
those of groups DC and M. 
Renal and hepatic failures are known to be the long-term consequences of diabetes 
(DCTT, 2007; Nordwall et al., 2004). Possible effects of the combined treatment on hepatic 
tissue may also be demonstrated by comparing the plasma levels of AST and ALT activity. 
Although there were statistically significant differences between the groups, the AST and ALT 
activities in all the groups were within the normal range (77 – 157 U/L and 24 – 53 U/L, 
respectively) (Suckow et al., 2006). Histological examination of the kidney and liver did not 
show obvious signs of abnormality. Typical cases of diabetes-induced hepatic damage would 
show fibrosis, derangement of the architecture, portal hypertension and in some instances, 
irreversible derangement of the morphology of the circulatory ducts (Nordwall et al., 2004). 
Histological analysis of the liver sections from treated animals did not show any visible changes 
in morphology compared with the non-diabetic control. Large nodules of matrix within 
mesangial areas with lesser increase in mesangial cellularity (DCTT, 2007, DCTT, 2000) that 
occur in diabetic nephropathy were not seen in the kidney sections obtained from groups SB and 
MSB rats. 
Of the miscellaneous biomarkers used in the study, kidney isoprostane, plasma CRP and 
glucagon contents in group MSB were statistically significantly different compared with the 
diabetic control and group M rats. Isoprostanes are secondary products of lipid peroxidation; 
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reduction in their levels suggests a reduction of oxidative stress levels in chronic disease states 
(Onaran et al., 2006). Plasma CRP is used as an inflammatory marker indicating susceptibility to 
cardiovascular complications of diabetes. Thus, as with isoprostanes, a reduction in plasma CRP 
levels would indicate a state of reduced oxidative stress leading to a reduced probability of 
cardiovascular-related complications. It is significant that group MSB showed reductions in both 
these parameters, indicating the potential of the combination to reduce such complications in the 
diabetic state. 
The results of this study show alleviation of oxidative stress by SB and MSB in the STZ-
induced diabetic rat model. S. baicalensis has the potential to reduce oxidative stress in diabetes 
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BAICALIN MEDIATED ANTI-DIABETIC EFFECT ON STREPTOZOTOCIN-






The herbal extract of S. baicalensis contained the bioactive flavonoid constituents of baicalin, 
baicalein and wogonin. In vitro analysis of these flavonoids in a human umbilical vein 
endothelial cell line stressed with high glucose conditions revealed baicalin to have the highest 
reduction in the glucose-induced reactive oxygen species content. Therefore, this study 
investigated the antioxidant and anti-diabetic effects of baicalin, as well as its effects in 
combination with the anti-diabetic drug metformin in an in vivo streptozotocin-induced diabetic 
rat model. Three groups of streptozotocin-induced diabetic rats were given the following 
treatments for 30 days: (1) metformin 500 mg/kg, (2) baicalin 120 mg/kg, (3) metformin 500 
mg/kg + baicalin 120 mg/kg. In addition, vehicle-treated diabetic and non-diabetic controls were 
used in the experiment. The rats treated with baicalin and metformin + baicalin had significantly 
elevated (p < 0.05) hepatic activities of superoxide dismutase, catalase and glutathione 
peroxidase compared with the vehicle- and metformin-treated groups. Plasma and hepatic lipid 
peroxide concentrations of the baicalin- and baicalin + metformin-treated groups had 
significantly reduced (p < 0.05). In addition, baicalin had significantly reduced plasma and 
hepatic triglycerides and cholesterol levels. The study thus showed that baicalin mitigated 
oxidative stress as well as enhanced the anti-diabetic effect of metformin by improving the 
antioxidant status.  
 







 Baicalin was the major compound found in the freeze-dried ethanolic extract of S. 
baicalensis. However, it was necessary to make out the primary bioactive flavonoid constituent 
through an in vitro study. Human umbilical vein endothelial cells (HUVEC) stressed with a high 
glucose condition was utilized to identify the primary constituent in the herbal extract which was 
responsible for reducing the production of ROS. Nishikawa et. al. (2000) reported increased 
production of ROS in hyperglycemic conditions in bovine aortic endothelial cells. Lee et al. 
(2008) and Tsuneki et al. (2007) utilized a similar cell-based model using HUVECs to 
investigate the protective effects of various compounds against high-glucose-induced oxidative 
stress. In conclusion, baicalin was identified as the primary flavonoid responsible for the 
reduction of ROS in the HUVEC model of hyperglycemia. 
 A further in vivo study in STZ-induced diabetic Wistar rats was carried out to highlight 
baicalin as the primary bioactive compound in the freeze-dried ethanolic herbal extract of S. 
baicalensis. In addition, the antioxidant and anti-diabetic activity of baicalin in STZ-induced 
diabetic Wistar rats has not been investigated to date. With reference to our previous study on S. 
baicalensis, the effects of the flavonoid in combination with metformin was also investigated. As 
with the previous study, it was one of the objectives of this study to demonstrate whether the 
addition of baicalin to metformin could potentially increase the antioxidant defenses as well as 




4.2 MATERIALS AND METHODS 
 
 Metformin and baicalin were purchased from Sigma Chemical Company (St Louis, MO). 
The purity of baicalin is verified in house using high performance liquid chromatography. All 
other chemicals used were of analytical grade and purchased from either or Sigma Chemical 
Company or from BDH Chemicals (BDH Ltd., Poole, UK), unless otherwise specified. 
 
4.2.1 ORAC activity measurement 
 Chemically, the peroxyl radical scavenging activity of baicalin, baicalein and wogonin 
was analyzed using the high throughput ORAC assay measurement as described by Huang et al 
(2002).  
 
4.2.2 In vitro assessment of flavonoid bioactivity 
 HUVECs (Vec Technologies, Inc.) were cultured in gelatin-coated flasks in MCDB-131 
complete medium (Vec Technologies, Inc.) and maintained at 37 0C in a humidified 95 % air- 
5% CO2 atmosphere. The medium was replenished every two to three days and the cells were 
sub-cultured at confluence. Cells from passages six to eight were used for the experiments. The 
glucose stressed condition was induced at a concentration of 30 mM in the cell culture medium, 
whereas the non-stressed control group was incubated at a glucose concentration of 5 mM. The 
high glucose condition was applied onto the cells for 3 days before the respective bioactivity 
measurements were carried out. 
 The fluorescent probe, 5-(and-6)-chloromethyl-2’,7’-dichlorodihydro-fluorescein 
diacetate (CM-H2DCFDA, Molecular Probes, USA), was used as a marker of intracellular ROS, 
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and fluorescence intensity was measured using a microplate reader (Safire2, Tecan). Baicalin, 
baicalein and wogonin were introduced at concentrations of 1, 10, 20, 100, 200 and 400 µM to 
105 cells/ml (glucose stressed cells) in a microplate and incubated for 24 hours before the ROS 
levels were measured. 
 The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay was used 
to assess cell viability from the treatments. 10 µl 10 mM H2O2 in Krebs-Ringer Bicarbonate 
Buffer (KRBB) or KRBB alone (control) was added to 90 µl of 105 cells/ml in each well of a 96-
well plate. After 24 hours of incubation, 10 µl 5mg/ml MTT solution was added. After further 4 
hours of incubation, 90 µl 10% SDS in 0.01 N HCl was added, before the absorbance at 570 nm 
was read. 
 
4.2.3 In vivo study of baicalin 
 Diabetes was induced in the Wistar rats as per the methods described in the previous 
chapters. The diabetic rats were divided into 4 groups (each n = 6) with the following treatments: 
(1) M - metformin 500 mg/kg; (2) B - baicalin 120 mg/kg; (3) MB - metformin 500 mg/kg and 
baicalin 120 mg/kg; (4) DC - diabetic control. A non-diabetic control (NDC) was also used in the 
experiment. The dosage of baicalin administered to the rats was calculated with reference to the 
previous in vivo study on S. baicalensis and the percentage of baicalin contained in the freeze-
dried extract of this herb. To make a fair comparison, the dosage of metformin remained 
unchanged as per our previous study as well. The respective treatments were orally administered 
twice daily for 30 days. The body weight and food and water intakes of the rats were monitored 
on a daily basis. Blood was collected from the tail vein of the rats for monitoring of weekly 
blood glucose levels, TC, TG and plasma lipid peroxide concentrations. On the evening of day 
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30, the rats were fasted overnight and euthanized the following morning by decapitation. Blood 
was collected by drainage from the carotids following euthanasia and kept in 200 µL aliquots at 
­80 0C till time for assay. The liver, pancreas and kidney of the rats were removed, sectioned into 
0.5 g aliquots, immersed in liquid nitrogen and stored at ­80 0C till the time for assay. 
 
4.2.4 Catalase (CAT), Superoxide Dismutase (SOD) and Glutathione Peroxidase (GPx) 
enzyme activities and expression and measurement of lipid peroxide contents 
 The same methods as per section 3.2.6 in Chapter 3 were used in this study as well.  
 
4.2.5 Determination of Hepatic TG, TC and Lipase Activity 
 The same methods as per sections 3.2.9 and 3.2.10 in Chapter 3 were used in this study as 
well.  
 
4.2.6 Other Biomarkers, Enzymes, and Hormones 
 Quantifications for glucose-6-phosphatase (G-6-Pase) activity, hepatic glycogen content, 
hepatic glycogen synthase content, and kidney 8­isoprostane F2α (isoprostane) content were 
carried out using MarkerGene™ ELISA assay kits.  
 
4.2.7 Statistical Analyses 
 Results are reported as mean ± standard error of the mean (SEM). Statistical differences 
among groups were calculated by using one-way ANOVA and two-way ANOVA where 
applicable, using SPSS version 12.0. Results were considered significant when p values 
generated from post-hoc comparisons were < 0.05. Post-hoc comparisons were conducted with 




4.3.1 In vitro identification of the primary bioactive constituent 
 
Table 4.1 ORAC values of baicalein, baicalin and wogonin. Values are expressed as mean ± 
SEM 
Flavonoid ORAC value (µmol TE/g) 
Baicalein 4729 ± 271 
Baicalin 365 ± 45 
Wogonin 98 ± 11 
 
The ORAC values of baicalin, baicalein and wogonin are shown in Table 4.1. Baicalein 
had the highest ORAC value followed by baicalin and wogonin. The in vitro quantification of 
ROS contents in glucose stressed HUVECs when treated with the respective dosages of baicalin, 
baicalein and wogonin are shown in Figure 4.1. Baicalin showed the highest reduction in ROS 
levels compared with the glucose stressed control group (p < 0.05), whereas wogonin showed the 
lowest reduction. 
It was also observed that the effect of baicalein on the ROS levels was not dose-
dependent. The cells which received 200 and 400µM of baicalein showed higher levels of ROS 
than the cells which received 100µM. It maybe hypothesized given the structure of baicalein, that 
the three –OH groups on the A-ring is initiating a pro-oxidant effect which results in the 
production of ROS rather than initiating a scavenging effect. 
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Despite the contradictions in the ORAC values and the in vitro reductions of ROS levels, 
baicalin was chosen as the compound to be studied in vivo in the STZ-induced diabetic Wistar rat 
model. Baicalin was the compound with the highest percentage content in the S. baicalensis 
herbal extract. Baicalin also had the highest reduction in ROS levels, although baicalein had a 






























Figure 4.1 The ROS contents in the HUVECs treated with the various dosages of baicalin, 
baicalein and wogonin compounds. Values are expressed as mean ± SEM. The average value per 






4.3.2 Daily Food and Water Intakes 
According to Figure 4.2A, groups M, B and MB had statistically significant decreases in 
the daily water intake compared with the diabetic control (p < 0.05). The decrease in the water 



















































































Figure 4.2 Effects of metformin, baicalin and metformin + baicalin on (A) daily water intake; 
(B) daily food intake; and (C) plasma leptin content of STZ-diabetic Wistar rats. Values are 
expressed as mean ± SEM. Each group includes 6 rats per treatment. * p < 0.05 versus the 
diabetic control; † p < 0.05 versus the metformin-treated group. 
 
 104 
The daily food intakes of groups M, B and MB were statistically significantly lower 
compared with the diabetic control (p < 0.05) (Figure 4.2B), but the intakes did not reach the 
levels of the non-diabetic controls at the end of the period of treatment. The reduction in the food 
intake may be associated with the increase in the plasma leptin levels which were measured at 
the end of the study, as shown in Figure 4.2C. A statistically significant increase in the plasma 
leptin levels was observed in groups M, B and MB compared with the diabetic control (p < 0.05) 
 
4.3.3 CAT, SOD, GPx and GST Activity   
An improvement in the antioxidant enzyme activities (compared with the diabetic 
control) was observed in groups B and MB (p < 0.05) at the end of the study (Figure 4.3A-C). 
Western blot analysis (Figure 4.3D-E) of the antioxidant enzymes also indicated a statistically 
significant increase in protein expression in groups B and MB compared with the diabetic control 
and group M (p < 0.05). It may be concluded that baicalin stimulated the protein expression of 






Figure 4.3 Effects of metformin, baicalin and metformin + baicalin on the hepatic (A) CAT 
activity; (B) SOD activity; (C) GPx activity; (D) protein expression of CAT, SOD and GPx; (E) 
representative Western Blot images of the protein expressions of CAT, SOD and GPx in STZ-
diabetic Wistar rats. The values were measured on day 30 and are representative of 6 rats per 
group. Results are expressed as mean ± SEM. * p < 0.05 versus the diabetic control; † p < 0.05 




























































































































4.3.4 Lipid Peroxide Levels in Liver, Kidney and Pancreas 
 The plasma lipid peroxides were measured on a weekly basis (Figure 4.4A). A 
significant decrease in plasma lipid peroxide levels was observed in groups M, B and MB from 
week 2 onwards, compared with the diabetic control (p < 0.05).  From week one onwards group 
MB was found to have an enhanced reduction of lipid peroxides (p < 0.05) compared with group 
M.  
 
Figure 4.4 Effects of metformin, baicalin and metformin + baicalin treatments of STZ-diabetic 
Wistar rats on (A) weekly plasma lipid peroxide concentrations; (B) hepatic lipid peroxide 
contents; (C) kidney lipid peroxide contents; (D) pancreatic lipid peroxide contents The lipid 
peroxide contents are expressed as mean ± SEM and represent the analysis of 6 rats per group. * 
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The lipid peroxide contents of the liver, kidney and pancreas were measured at the end of 
the study (Figure 4.4B-D). An enhanced reduction in the hepatic lipid peroxide was observed 
when comparing the concentrations in groups M and MB (p < 0.05). However, this decrease was 
not observed with kidney and pancreatic lipid peroxide contents in these two groups, although 
there was a statistically significant reduction in lipid peroxide contents in all the treatment groups 
compared with the diabetic control (p < 0.05). 
 
4.3.5 Plasma Glucose, Plasma and Pancreatic Insulin Contents 
 The plasma blood glucose levels were measured on a weekly basis throughout the 30-day 
treatment. As shown in Figure 4.5A, groups M and MB showed statistically significant 
reductions of plasma glucose from week 1 onwards and group B from week 2 onwards compared 
with the diabetic control (p < 0.05).  
None of the groups’ plasma glucose concentrations had reached the levels of the non-
diabetic control at the end of the 30-day treatment. The plasma insulin content of MB was 
significantly higher than that of group M (p < 0.05) indicating an enhancing effect of the 
combined treatment (Figure 4.5B). The enhancement was also observed in the pancreatic insulin 




Figure 4.5 Effects of metformin, baicalin and metformin + baicalin on (A) weekly blood glucose 
levels; (B) weekly plasma insulin concentration; and (C) pancreatic insulin content in STZ-
diabetic Wistar rats. Values are expressed as mean ± SEM. Each group includes 6 rats per 
treatment. * p < 0.05 versus the diabetic control; † p < 0.05 versus the metformin-treated group. 
 
4.3.6 Plasma and Hepatic TG and TC Contents, and Lipase Activity 
Plasma TG and TC levels were measured on a weekly basis. Significant reductions in 
plasma TG (Figure 4.6A) were observed in groups M, B and MB compared with the diabetic 
control (p < 0.05). The reductions in plasma TG in groups B and MB were statistically 
significant compared with group M (p < 0.05) indicating the hypotriglyceridaemic effect of the 
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show a significant reduction in hepatic TC; however, a significant reduction was observed in 

































Figure 4.6 Effects of metformin, baicalin, and metformin + baicalin on (A) weekly plasma TG 
concentrations; (B) weekly plasma TC concentrations; (C) hepatic TG; (D) hepatic TC; (E) 
hepatic lipase activity in STZ-diabetic Wistar rats. Values are expressed as mean ± SEM. Each 
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As shown in Figure 4.6C-D, hepatic TC and TG contents of group MB were also 
significantly increased compared with group M (p < 0.05). The results of the hepatic lipase 
activity are shown in Figure 4.6E. Groups M, B and MB showed significant decreases (p < 0.05) 
in lipase activity compared with the diabetic control. The lipase activities in groups B and MB 
were significantly reduced (p < 0.05), compared with group M. 
 
4.3.7 Glycogen Synthesis 
The hepatic glycogen contents (Figure 4.7A) had a statistically significant increase in 
groups M, B and MB compared with the diabetic control (p < 0.05) which corresponded with the 
glycogen synthase activities of these treatment groups (Figure 4.7B). The enhanced glycogen 
synthase activities may be attributed to the influence of increased hepatic glucose-6-phosphatase 
(G-6-Pase) activities (Figure 4.7C). Groups M, B and MB had statistically significant increases 
in hepatic G-6-Pase activities compared with the diabetic control (p < 0.05). The influence of 
hepatic G-6-Pase would have resulted in a reduction of glycogenolysis and a stimulation of 
glycogen synthesis through glycogen synthase. Group MB had a statistically significant increase 
in these enzyme activities compared with group M (p < 0.05) indicating the enhancing effect of 






Figure 4.7 Effects of metformin, baicalin and metformin + baicalin on (A) hepatic glycogen 
contents; (B) hepatic glycogen synthase activity; (C) hepatic glucose-6-phosphatase activity in 
STZ-diabetic Wistar rats. Values are expressed as mean ± SEM. Each group includes 6 rats per 
treatment. * p < 0.05 versus the diabetic control; † p < 0.05 versus the metformin-treated group. 
 
4.3.8 Other Bio-markers and Hormones 
 The values of the other parameters – AST, ALT, CRP and kidney 8­isoprostane F2α 
(isoprostane), are shown in Table 2 of the appendix. Except for CRP and isoprostane, the 
parameters had not improved in the MB-treated group compared with group M as well as the 
diabetic control (p > 0.05). With regards to the AST and ALT values, despite the variances, the 
AST and ALT activities in groups DC and B were within the normal ranges of 77 – 157 U/L and 







































































































treatments or possible organ damage due to the diabetic condition. The AST and ALT values of 
groups M and MB were above the stated normal ranges. However, histological analysis of 
hepatic tissues did not indicate any typical signs of toxicity-induced tissue damage, such as 
fibrosis of the hepatocytes. In addition, typical in vivo conditions showing toxicity-induced tissue 
damage would show multiple levels of activity increases of AST and ALT which was not 
observed in this study. Thus, it may be concluded that the increases in AST and ALT activities in 




 Baicalin had increased the antioxidant enzyme activity by increasing the expression of 
the proteins as observed from the Western Blot data. Reduction of plasma, hepatic, kidney and 
pancreatic lipid peroxides were an indirect confirmation of reduced oxidative stress levels as a 
result of increased antioxidant enzyme activity. Recent reports on STZ-induced diabetic Wistar 
rats have shown flavonoids to ameliorate diabetes-induced oxidative stress (Lee et al., 2007). 
Increased expression of antioxidant enzymes would in turn result in the reduction of lipid 
peroxide contents in the organs. Metformin was observed to have efficiently reduced the 
hyperglycemic status compared with the diabetic control. Thus, as shown by previous reports, 
while metformin may not directly scavenge free radicals, the elevations in antioxidant enzymes 
in group M rats could be due to reduced generation of ROS resulting indirectly from reduced 
hyperglycemia, thus ultimately diminishing the oxidative damage (Onaran et al., 2006).  
 Baicalin has an ORAC value of 365 µmol TE/g. On molecular basis, the radical 
scavenging activity of baicalin is only 0.16 times of that of Trolox, the water soluble vitamin E 
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analogue.  In addition, Baicalin is a water soluble compound due to the glucuronic acid group. 
Therefore, it may be suggested that the decrease of lipid peroxide values may not necessarily be 
due to the lipid peroxyl radical scavenging capacity but due to an indirect impact on stimulating 
antioxidant enzyme expressions.  It is possible, with reference to the structure of baicalin, the 
phenolic groups of the A ring may chelate transition metals such as copper and iron, to prevent 
Fenton like reaction from occurring, thus reduce the oxidative stress. Our results illustrate the 
complexity of antioxidant mechanisms in vivo. In vitro chemistry based assays speaks little when 
it come to bioactivity of polyphenolic antioxidants (Frankel and Finley, 2008). 
 The enhancement of antioxidant activity in group MB may have been due to the two 
separate pathways of reducing oxidative stress of baicalin and metformin. As mentioned before, 
reduction of plasma glucose levels by metformin would result in a reduction of free radical 
production through the respective pathways (Rother, 2007; Brownlee, 2005). Production of free 
radicals itself have been known to hinder the secondary and tertiary protein structures of 
antioxidant enzymes (Brownlee, 2005; Dierckx et al., 2003). Thus, reduction of free radical 
production may have resulted in the prevention of damage to the antioxidant enzymes, which 
was initiated by metformin. In addition, baicalin may have induced the expression of antioxidant 
enzymes as explained previously. Thus, the combined effect may have resulted in an 
enhancement of the antioxidant enzyme activities in group MB.  
 The kidney isoprostane contents in groups B and MB were statistically significantly 
reduced compared with the diabetic control and group M rats indicating reduced oxidative stress 
levels. Reduction in plasma CRP levels would indicate a state of reduced oxidative stress leading 
to a reduced probability of cardiovascular-related complications in these two groups. Groups B 
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and MB showed reductions in plasma CRP levels as well, indicating the potential of the 
combination to reduce such complications in the diabetic state.  
 Baicalin had reduced plasma and hepatic TG and TC contents which was not observed in 
the metformin-treated group. A recent study has shown polyphenols to stimulate hepatocellular 
AMPK activity and lipid levels, as well as hyperlipidemia and atherogenesis in type 1 diabetic 
mice, which is similar in terms of the mechanism to the course of action of metformin. Existing 
evidence demonstrated that the availability of FFA for oxidation by muscles and other tissues 
may lead to impairment of carbohydrate oxidation and lead to glucose intolerance as seen in 
obesity and obese diabetics (Unger and Orci, 2001). In addition, FFA can stimulate hepatic 
gluconeogenesis and alter pancreatic insulin release as well as pathways of glucose metabolism 
(Unger and Orci, 2001). Therefore, the reduction of circulating TG and TC is an important aspect 
of the treatment of diabetes which was not achieved with metformin in this study. 
 In summary, this study has shown that baicalin to be an efficient mitigator of 
hyperglycemia-induced oxidative stress when used alone or in combination with metformin. The 
importance of maintaining the redox balance as well as reducing the elevations in plasma glucose 
levels has been recognized as essential and proficient methods in combating diabetic macro- and 
micro-vascular complications. Thus, the results of this study add strength to the hypothesis that 
an increase in antioxidant activity plays a role in the prevention of hyperglycemia-induced long-
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BAICALIN REDUCES MITOCHONDRIAL DAMAGE IN 

















Hyperglycemia-induced superoxide production in the mitochondria leads to mitochondrial 
membrane damage and is the primary cause of diabetic micro- and macro-vascular 
complications. This study chapter is a continuation of the research work carried out in the 
previous chapters, with a focus on the mitochondrial dynamics observed in the various treatment 
groups. Transmission Electron Microscopy imaging of pancreatic β-cells revealed loss of 
integrity of the inner membrane of the mitochondria in the diabetic rats, which was not observed 
in the baicalin-treated group. In addition, baicalin and the combined treatment of metformin and 
baicalin had statistically significantly reduced (p < 0.05) the number of mitochondria with a 
damaged membrane compared with the diabetic control as well as the metformin-treated group 
in the hepatic tissues. Baicalin had also statistically significantly increased the plasma leptin 
content (p < 0.05) versus the diabetic control, which in turn had effected the total expression of 
hepatic mitochondria per cell indicating its effects in SIRT1 activity. The increase in 
mitochondrial number was further complemented with similar trends in the hepatic citrate 
synthase activity. In summary, baicalin had reduced the hyperglycemia-induced mitochondrial 
membrane damage as well as enhanced the effects of metformin as was observed in the results 
from the metformin and baicalin treated groups. 
 







 As explained in Chapter 2, hyperglycemia-induced production of superoxide in the 
mitochondria is known to be the key cause of diabetic complications (Brownlee, 2005). Impaired 
mitochondrial activity has been detected in insulin-resistant patients with type 2 diabetes 
(Petersen et al., 2003). Furthermore, in vivo NMR spectroscopy studies in type 2 diabetic patients 
have shown a severe decline in mitochondrial function (Petersen et al., 2003).   
 Mitochondrial superoxide is important in the maintenance of normal physiological 
conditions and functions. Under normal physiological conditions, superoxide participates in 
various cell functions. However, loss of control of superoxide production which results in its 
excessive production is associated with disease pathologies such as diabetes. ROS that are 
produced by mitochondria are released into the mitochondrial matrix or the intermembrane 
space. Each ROS pool is likely to be involved in different oxidative-stress-induced cellular 
mechanisms and damage. These damages result in diabetic micro-vascular complications such as 
neuropathy, nephropathy and cardiovascular disease (Cheng and Zochodne, 2003; Coppey et al., 
2001; Packer, 2000).  
 This study was designed to investigate the effects of baicalin on the mitochondria, 
especially in terms of hyperglycemia-induced mitochondrial membranal damage and its effects 
on markers of calorie-restriction. In addition the study also demonstrates the effects of the 
combination of metformin with baicalin which can further reduce mitochondrial damage and 




5.2 MATERIALS & METHODS 
  
 Metformin and baicalin were purchased from Sigma Chemical Company (St Louis, MO). 
The purity of baicalin is verified in house using high performance liquid chromatography. All 
other chemicals used were of analytical grade and purchased from either or Sigma Chemical 
Company or from BDH Chemicals (BDH Ltd., Poole, UK), unless otherwise specified. 
 
5.2.1 In vivo study   
 The in vivo study was carried out as per Chapter 4. 
 
5.2.2 Hepatic citrate synthase activity  
 The hepatic citrate synthase activity was quantified according to Holmuhamedov et al 
(2002). In brief, hepatic tissue of the Wistar rats of the respective treatment groups were 
homogenized in phosphate buffer (pH = 7.4, 0.01mM) at a concentration of 0.1 mg/ml. The 
absorbance decrease in the deacetylation of acetyl co-A was measured at 412nm using a 
Shimadzu spectrophotometer. The protein concentration in each homogenized tissue sample was 
determined using the Bio-Rad protein assay. 
 
5.2.3 Transmission Electron Microscopy (TEM) imaging   
 Pancreatic and hepatic tissues of the Wistar rats were cut in one mm3 blocks and fixed in 
an aqueous solution containing 3% glutaraldehyde, 2.5% paraformaldehyde, 2 mM calcium 
chloride, 2% sucrose in 0.1 M cacodylate buffer and processed according to Le Couter et. al. 
(2001). Three blocks from different parts of each organ were used for processing. Following 
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processing, tissues were embedded in Epon / Araldite and sections were cut from epoxy blocks. 
The sections were mounted in 100-mesh Formvar coated copper grids for viewing. Imaging was 
performed using a Jeol 1210 transmission electron microscope and images were photographed 
using a Gatan US 4000MP digital camera. High resolution images of pancreatic β-cell 
membranal damage was obtained by controlling the opening and closing of the electron beam 
shutter in order to control the exposure time. The mitochondrial number as well as the number of 
damaged mitochondria in hepatocytes was quantified by grid counting according to the method 
by Baur et al., (2006). In brief, ten cells per tissue section were randomly selected and the grid 
was positioned on each of the chosen cells. The number of mitochondria were counted and 
collated per each square in the grid. The damage to the mitochondrial wall was evaluated through 
visual inspection and ranking in terms of overall pathology, on a scale of 0-4 with 0 being 




5.3.1 TEM imaging of the mitochondria 
 Qualitative TEM imaging of the mitochondria in the treatment groups revealed less 
damage to the mitochondrial membrane in pancreatic β-cells and hepatocytes compared with the 
vehicle-treated group as shown in Figures 5.1 and 5.2. Further high resolution imaging of the 
pancreatic β-cell mitochondrial membranes revealed collapsing of the inner membrane in the 
vehicle-treated group as seen in Figure 5.3.  
Intermittent structural alterations to the inner mitochondrial membrane were visible in the 
metformin-treated group as well as shown in Figure 5.3. In comparison, groups treated with 
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baicalin and metformin + baicalin did not indicate such structural damage to the inner 
mitochondrial membrane.  
 
DC           M 
    
    B          MB 
   
 
Figure 5.1 TEM images of the mitochondrial pathology in the pancreatic β-cells of the vehicle-
treated (DC) metformin-treated (M), baicalin-treated (B) and metformin + baicalin treated (MB) 
STZ-induced diabetic Wistar rats. The scale bars indicate 0.5 µm and 0.2 µm for the image of the 
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Figure 5.2 TEM images of the mitochondrial pathology in the hepatocytes of the vehicle-treated 
(DC) metformin-treated (M), baicalin-treated (B) and metformin + baicalin treated (MB) STZ-
induced diabetic Wistar rats. The scale bars indicate 0.5 µm and 0.2 µm for the image of the 
vehicle-treated group. The circle indicates collapsed mitochondria in the vehicle-treated group. 
 
According to Chan (2001) a circular appearance of the mitochondria indicates that the 
mitochondria are less likely to form fission products. This, in turn, may lead to excessive releases 
of ROS such as superoxide. There were more circular-shaped mitochondria in the baicalin- and 
metformin + baicalin-treated groups compared to the metformin-treated group indicating a 
higher probability of metformin to form fission products than the other treatment groups as 
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shown in Figures 5.1 and 5.2.   The addition of baicalin to metformin thus seemed to reduce this 
likelihood. 
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Figure 5.3 TEM images of the mitochondrial membrane pathology in the pancreatic β-cells of 
the vehicle-treated (DC) metformin-treated (M), baicalin-treated (B) and metformin + baicalin 
treated (MB) STZ-induced diabetic Wistar rats. The scale bars indicate 0.1 µm. The circle 
indicates the damage to the inner mitochondrial membrane in the vehicle- and metformin-treated 
groups. 
  
  The number of mitochondrial with damaged membranes had statistically significantly 
reduced in groups B and MB (p < 0.05) compared with the diabetic and metformin-treated 
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groups (Figure 5.4). This further ascertained the effect of baicalin in its protection against 
hyperglycemia-induced mitochondrial damage and its enhancement effect of metformin in the 
combined treatment. 
Mitochondrial numbers in hepatic cells have been known to be an indicator of calorie 
restriction. Exercise and reduction in calorie-intake have been shown to decrease the hepatic 
mitochondrial number by inducing the expression of endothelial nitric oxide synthase (eNOS) 
(Nisoli et al., 2005). A decrease in mitochondrial number has also been observed in the presence 































Figure 5.4 Number of mitochondria with damaged membranes in the hepatocytes of the various 
treatment groups. Values are expressed as mean ± SEM. Each group includes 6 rats per 
treatment.  * p < 0.05 versus the diabetic control, † p < 0.05 versus the metformin-treated group 
 
A comparison of the number of mitochondria per hepatocyte (Figure 5.5A) revealed a 
statistically significant increase in all the treatment groups compared with the diabetic control (p 
< 0.05) although none of the treatments had reached mitochondrial numbers on par with group 
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NDC. This trend was further complemented with the hepatic citrate synthase activity (Figure 
5.5B). The baicalin- and metformin + baicalin- treated groups also had a statistically significant 
increase in mitochondrial number compared with the metformin-treated group (p < 0.05). The 
mitochondrial numbers show a positive correlation to the plasma leptin content as in Figure 




























































































Figure 5.5 Effects of metformin, baicalin and metformin + baicalin on (A) the hepatic 
mitochondrial number (B) hepatic citrate synthase activities and (C) plasma leptin content of 
STZ-diabetic Wistar rats. Values are expressed as mean ± SEM. Each group includes 6 rats per 






 ROS are closely linked to a variety of oxidative stress-related diseases such as diabetes, 
Alzheimer’s disease, Parkinson’s and cancer. As a byproduct of oxidative phosphorylation, a 
steady stream of reactive species results from mitochondria. ROS potentially cause damage to all 
cellular components. Structural alterations, biomolecule fragmentation, and oxidation of side 
chains are trade-offs of cellular energy production. In the event of structure alteration, the inner 
mitochondrial membrane becomes the primary prey to the generated ROS, thus resulting in its 
loss of integrity and subsequent collapsing (Schrauwen et al., 2001). As mentioned in the 
previous chapter, free radical quenchers or enhancers of enzymatic antioxidant activity such as 
baicalin are of therapeutic potential in the treatments of oxidative stress-induced diseases such as 
diabetes. The search for new protective remedies against damage caused by excessive free 
radical formation in mitochondria has accelerated over the past few years (Mills et al., 2003). 
Similar to the body’s own natural defenses against ROS, research has been primarily focused on 
molecules combining antioxidant utilities with recycling capacities. As shown by the TEM 
images, current anti-hyperglycemic agents such as metformin are inefficient in reducing free 
radical-induced oxidative damage to membranal structures such as the mitochondria, thus 
increasing the need to find better therapeutic agents to combat oxidative stress. This was further 
supported in comparing the weekly reduction of serum glucose levels as shown in Chapter 4 
(Figure 4.6A) and the number of damaged mitochondria in Figure 5.4. Despite the overall 
second highest reduction in the plasma glucose levels in the metformin-treated group, the 
number of damaged mitochondria in the hepatocytes had not reduced accordingly in this group. 
In comparison, although Baicalin was not efficient in reducing the serum glucose levels, it 
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showed a comparatively higher efficiency in reducing the mitochondria membrane damage 
compared with the metformin-treated group, as shown in Figure 5.4.  
 Baicalin has an ORAC value of 365 µmol TE / g. In addition, the phenolic groups in A 
ring of the baicalin structure is able to chelate transition metals such as copper and iron resulting 
in preventing Fenton like reactions from occurring, thus reducing the oxidative stress. Large-
scale double-blind trials investigating the use of antioxidants in diabetes have been carried out 
resulting in comprehensive conclusions that the reduction of oxidative stress leads to reducing 
the likelihood of developing diabetic micro- and macro-vascular complications (Rosen et al., 
2001). A few small-scale trials have also suggested the efficacy of the natural antioxidants such 
as α-tocopherol (vitamin E), ascorbate (vitamin C), Coenzyme Q, and α-lipoic acid, although in 
other trials, the efficacy of ascorbate and α-tocopherol were found to be ambiguous (West, 
2000). As these natural antioxidants can be given at high doses and have shown some efficacy in 
other degenerative diseases, there is a strong rationale for trialing them in diabetes (Murphy, 
2001). In addition, many other synthetic antioxidants are being developed, such as SOD- or 
catalase-mimetics that may be more potent than natural antioxidants and also have improved 
bioavailability, pharmacokinetics, and stability in diabetes (Salvemini et al., 1999). In fact, 
synthetic antioxidants which are targeted to accumulate within the mitochondria are known to 
offer more protection than untargeted antioxidants (Salvemini et al., 1999). However, the 
advantage of naturally occurring antioxidants such as baicalin, is their safety and greater 
tolerability. Nevertheless, despite the ongoing research and therapeutic clinical trials, no 
pharmaceutical agents specifically designed to deliver a therapeutic compound to mitochondria 
have yet reached the market, but it is likely that a significant number of essential nutrients, 
including vitamins C and E, fulfill at least part of their function by controlling the surge of 
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reactive byproducts of the oxidative phosphorylation process and ATP generation in 
mitochondria (Dhanasekaran et al., 2005). 
 Mitochondrial dynamics have become the current focus of cell biologists in determining 
disease conditions. Studies have shown that mitochondrial fission precedes apoptosis and 
programmed cell death induced by high levels of oxidative stress (Youle and Karbowski, 2005; 
Chan, 2006). In the event of mitochondrial fission, not only do the mitochondrial membranes 
rupture but so do their contents, including the matrix compartment that contains mitochondrial 
DNA. The fragmentation of mitochondria, through fission, facilitates the release of 
mitochondrial proteins and metabolites such as ROS that trigger intracellular oxidative stress and 
cell death (Houstis et al., 2006). Given the important role of mitochondrial dynamics in human 
physiological processes, it would not be surprising to find additional disease conditions which 
are caused by oxidative stress leading to mitochondrial fusion and fission. Intuitively, it is also 
easy to imagine how mitochondrial fusion and fission can change the morphologic characteristics 
of mitochondria as was seen in the TEM images in this study. 
 Mitochondrial biogenesis in liver and muscle is controlled, in large part, by the 
transcriptional co-activator, PGC-1α, the activity of which, in turn, is positively regulated by 
SIRT1-mediated deacetylation and leptin expression (Yoon et al., 2001; Bordone and Guarente, 
2005). The SIRT1 pathway is exhaustively studied in the realms of calorie-restriction. SIRT1 is 
known to be an enzyme that removes acetyl groups from specific nuclear proteins and has been 
linked to the regulation of aging. Recent evidence also suggests that SIRT1 controls hepatic 
glucose metabolism by serving as a sensor of the metabolic status in hepatocytes. A higher 
expression of leptin would induce the biogenesis of mitochondria in the hepatocytes. Several 
explanations may be highlighted with regards to the observed trends in the mitochondrial number 
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in the hepatoyctes of the different treatment groups. A lesser extent of mitochondrial fission may 
result in a higher number of intact mitochondria in groups B and MB, compared with groups DC 
and M. The mitochondrial numbers in the treatment groups of this study are also consistent with 
the citrate synthase activities and the plasma leptin content as respectively shown in Figures 
5.5B and C, indicating the induction of mitochondrial expression by leptin. With increased leptin 
levels to be a casual factor for reduced calorie consumption (Le Couteur et al., 2001), the trend in 
the mitochondrial number is consistent with previous reports showing an increased hepatic 
mitochondrial number in conditions of restricted calorie intake (Nisoli et al., 2005; Lopez-Llusch 
et al., 2006). Many flavones have been shown to be good activators of SIRT1 deacetylation. As 
indicated by the mitochondrial number, citrate synthase activity and the plasma leptin content in 
this study, baicalin or its metabolites in vivo may exhibit calorie restriction mimetic activity 
(Liebiger and Berggren, 2006). However, this activation pathway needs to be explored in 
addition to its radical scavenging activity as a potential mechanism in reducing oxidative damage 
to mitochondria. 
 TEM is a powerful tool which can be used for imaging mitochondrial membrane damage 
in oxidative stress-related disease conditions such as diabetes. High resolution TEM imaging 
with a controlled exposure time was able to reveal inner mitochondrial membrane damage 
consistent with increased production of ROS and RNS due to hyperglycemia. Compared with 
currently used methods such as fluorescence in the quantification of mitochondrial damage, 
monitoring these effects using TEM could be concluded as a relatively qualitative method. 
However, given the non-specificity of most probes (fluorescent or non-fluorescent) used in ROS-
based assessments of the mitochondria, TEM could be stated as being comparatively less 
defective, given the fact that mitochondria are directly imaged. Nevertheless, the methods of 
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quantification of the ROS-initiated mitochondrial damage through TEM are still at its infancy 
and are in the process of gaining standardization.  
Despite the comparatively higher reduction in plasma glucose levels, the treatment of oral 
anti-hyperglycemic agents such as metformin were seen to be inefficient in reducing inner 
mitochondrial membrane damage compared with antioxidant agents such as baicalin. Thus, the 
combined treatment of baicalin with metformin was able to have a comparatively better effect on 
the pathology of the mitochodria. Qualitative assessment of mitochondrial dynamics revealed 
that baicalin had also reduced the probability of mitochondrial fission, a characteristic which was 
not observed in the metformin treatment. Baicalin was also able to increase mitochondrial 
number, indicating its ability to stimulate pathways which reduce the calorie intake as seen by 
the trends in the plasma leptin content. It had enhanced the effect of metformin in this aspect as 
well. The results indicate the importance of the mitochondrial pathology in oxidative stress-
related disease conditions such as diabetes. Antioxidant agents such as baicalin may serve as 
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BAICALIN UPREGULATES THE GENETIC EXPRESSION OF ANTIOXIDANT 

















The primary purpose of this study was to characterize and investigate the antioxidant and anti-
diabetic activities of baicalin in type 2 diabetic Goto-Kakizaki rats. Four groups of Goto-
Kakizaki rats (n = 6) were subjected to the following oral treatments for 30 days: (1) metformin 
– 500 mg/kg (2) baicalin – 120 mg/kg (3) metformin (500 mg/kg) and baicalin (120 mg/kg) and 
(4) vehicle-treated diabetic controls receiving distilled water. The plasma glucose, triglyceride, 
total cholesterol, lipid peroxide and protein carbonyl contents were measured on a weekly basis. 
The antioxidant enzyme activities as well as their expression were quantified using Western Blot, 
microarray and RT-PCR. The respective analyses showed that the baicalin- and the metformin 
and baicalin-treated groups had a statistically significant increase (p < 0.05) in the activity and 
expression of the antioxidant enzymes (superoxide dismutase, catalase and glutathione 
peroxidase) compared with vehicle- and metformin-treated groups. The oxidative stress markers 
of plasma lipid peroxide and protein carbonyl contents had reduced in these groups as well. 
These treatment groups had also reduced plasma total cholesterol and triglyceride levels 
compared with vehicle-treated and metformin-treated groups (p < 0.05). In conclusion, baicalin 
was seen to be an efficient antioxidant in reducing hyperglycemia-induced oxidative stress 
through the increased expression of antioxidant enzyme activities. It was also an efficient anti-
hypertriglyceridaemic as well as anti-hypercholesterolaemic agent compared with metformin. 
 







This study was designed to examine the antioxidant and anti-diabetic effects of baicalin 
in the genetically modified type 2 diabetic Goto-Kakizaki rats. In brief, antioxidant parameters 
such as the enzyme activities of SOD, CAT and GPx, as well as diabetic parameters such as 
plasma glucose, insulin, TC and TG were quantified during the experiment. Plasma lipid 
peroxide levels and plasma protein carbonyl contents were measured as markers of oxidative 
stress. The effects of baicalin on markers of calorie-restriction were also investigated.  As per the 
previous chapters, the parameters were studied in comparison with the anti-hyperglycemic drug 
metformin as well. 
 
6.2 MATERIALS AND METHODS 
 
 Metformin and baicalin were purchased from Sigma Chemical Company (St Louis, MO). 
The purity of baicalin was verified in-house using high performance liquid chromatography. All 
other chemicals used were of analytical grade and purchased from either or Sigma Chemical 
Company or from BDH Chemicals (BDH Ltd., Poole, UK), unless otherwise specified. 
 
6.2.1 In vivo study 
 The study was carried out according to the guidelines of the IACUC. GK rats weighing 
250 ­ 300 g each were obtained from CLEA Inc., Japan and housed in a room with a controlled 
temperature (22 ± 3 0C) on a 12: 12 light/dark cycle. Unless otherwise specified, animals had 
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free access to pelleted food containing the AIN-93M Maintenance Purified Diet (Glen Forrest, 
WA, Australia) with tap water ad libitum. The diabetic rats were divided into four treatment 
groups (each n = 6): (1) M - metformin 500 mg/kg; (2) B - baicalin 120 mg/kg; (3) MB - 
metformin 500 mg/kg and baicalin 120 mg/kg; (4) DC – vehicle-treated diabetic control. 
Metformin and baicalin were dissolved in deionized water before administering to the rats. The 
treatments were administered to the rats by oral gavaging for a period of 30 days. The body 
weight and food and water intakes of the rats were monitored on a daily basis. Blood was 
collected from the tail vein of the rats for monitoring of weekly plasma glucose, lipid peroxide 
and protein carbonyl concentrations. On the evening of day 30, the rats were fasted overnight 
and euthanized the following morning by carbon dioxide inhalation. Blood was collected by 
drainage from the carotids following euthanasia and kept in 200 μL aliquots at ­80 0C till time for 
assay. The hepatic, pancreatic and cardiac tissues of the rats were removed, sectioned into 0.5 g 
aliquots, immersed in liquid nitrogen and stored at ­80 0C till the time for assay. 
 
6.2.2 Quantification of antioxidant enzyme activities and oxidative stress 
 The same methods as per sections 3.6.2 and 3.2.7 in Chapter 3 were used during this 
experiment as well. 
 
6.2.3 Isolation of RNA, microarray and real-time polymerase chain reaction (RT-PCR) 
analyses 
 The rat hepatic tissue samples (0.5 g) were placed in liquid nitrogen. Total RNA was 
isolated from the frozen liver tissues with the TRIzol reagent (Invitrogen, Carlsbad, CA, USA) 
according to the manufacturer’s protocol. All RNA isolated was quantified by spectrophotometry 
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and the purity was assessed at an optical density ratio of 260/280 nm. Total RNA was further 
purified with an RNeasy column (Qiagen, Chatsworth, CA), and used for cDNA synthesis. The 
first and second strand cDNA synthesis was performed using the GeneChip One-Cycle cDNA 
Synthesis Kit (Affymetrix, UK). Labeled cRNA was prepared using the GeneChip IVT Labelling 
Kit (Affymetrix, UK). Following the IVT reaction, the unincorporated nucleotides were removed 
using RNeasy columns (Qiagen, Milan, Italy). The cRNA was generated in duplicates from a 
pool of three different mRNA extractions. The cRNA was then transferred for hybridization onto 
the Affymetrix U133 Plus 2.0 GeneChips (Affymetrix, UK). The washing and staining procedure 
was performed in an Affymetrix Fluidics Station (Affymetrix, UK). The probe arrays were 
scanned at 560 nm using a GeneChip® Scanner 3000 confocal laser-scanning microscope 
(Affymetrix, UK). The readings from the quantitative scanning were analyzed by the Affymetrix 
Gene Expression Analysis Software. Results were normalized to glyceraldehyde-3-phophate 
deydrogenase (GAPDH) which was used as a housekeeping gene.  
For real-time polymerase chain reaction (RT-PCR) analysis of the antioxidant enzyme 
mRNA expression, reverse transcriptase reaction was performed using a SuperScript 
Preamplification System (Invitrogen, USA) for the first-strand cDNA synthesis. RT-PCR for 
amplification of cDNA was performed using a LightCycler (Roche Diagnostics, Mannheim, 
Germany). PCR for each sample was carried out in duplicate for all cDNAs and for the GADPH 
control. The PCR mixture (total volume 20 µL), which was prepared with nuclease-free water, 
contained 2.0 µL of LightCycler FastStart DNA Master SYBR Green 1 (Roche Diagnostics, 
Mannheim, Germany), 3 mM MgCl2, and a 5 µM concentration of each primer, together with 5 
µL of purified DNA or negative control. Primers used in this study (Table 3 of the appendix) 
were purchased from Sigma Chemicals (Singapore). The amplification protocol for cDNA was a 
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10 min denaturation step at 95 0C for polymerase activation; a “touchdown” PCR step of 10 
cycles consisting of 10 s at 95 0C, 10 s at 65 0C, and 30 s at 72 0C; followed by 40 cycles 
consisting of 10 s at 95 0C, 10 s at 55 0C, and 30 s at 72 0C. After slow heating (0.1°C per 
second) of the amplified product from 65 to 95 0C to generate a melting temperature curve 
(which served as a specificity control), the PCR samples were cooled to 40 0C. Fluorescence 
signals from the amplified products were quantitatively assessed using the LightCycler software 
program (version 3.5). Second-derivative maximum mode was chosen with the baseline 
adjustment set to the arithmetic mode. The relative expression level of each mRNA was 
determined by the Ct method, in which Ct value is the cycle number at which fluorescence signal 
crosses the threshold signal (Hoen et al., 2003). 
 
6.2.4 TEM imaging of the mitochondria in rat hepatocytes and hepatic citrate synthase 
activity 
 The same methods as per sections 5.2.2 and 5.2.3 in Chapter 5 were used during this 
experiment as well. 
 
6.2.5 Histological analysis 
 The rats’ hepatic, pancreatic and cardiac tissues were prepared for histological analysis as 
stated in section 3.2.15 in Chapter 3. 
 
6.2.6 Measurement of plasma glucose, leptin, TC and TG levels, hepatic lipase activity and 
plasma and pancreatic insulin contents 
 These parameters were measured according to the methods stated in sections 3.2.9 and 
3.2.10 in chapter 3. 
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6.2.7 Measurement of plasma CRP, tumor necrosis factor-α (TNF-α), AST and ALT 
contents   
 The plasma CRP and TNF-α concentration were determined by ELISA using assay kits 
purchased from Crystal Chemical Inc (Santa Monica, CA). Plasma AST and ALT activities were 
measured according to the method described in section 3.2.13 in chapter 3. 
 
6.2.8 Statistical Analyses 
 Results are reported as mean ± standard error of the mean (SEM). Statistical differences 
among groups were calculated by using one-way ANOVA and two-way ANOVA where 
applicable, using SPSS version 12.0. Results were considered significant when p values 
generated from post-hoc comparisons were < 0.05. Post-hoc comparisons were conducted with 




6.3.1 Hepatic antioxidant enzyme activities and expression and markers of oxidative stress 
 The hepatic SOD (Figure 6.1A) and CAT (Figure 6.2B) activities in groups B and MB 
had statistically significant increases (p < 0.05) compared with group DC and M. The GPx 
activities were increased in all the treatment groups compared with group DC (Figure 6.1C). 
However, the increase in the GPx activities of group B and MB were statistically significant 
compared with group M (p < 0.05). Thus, it may be concluded that baicalin had increased the 
antioxidant enzyme activities. In this aspect, baicalin was seen to be more efficient than 
metformin as well. Therefore, the increase in the antioxidant enzyme activities observed in group 
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MB would have been due to baicalin rather than metformin. Western Blot quantification of the 
antioxidant enzyme protein contents (Figure 6.1D and 6.1E) correlated with the respective 
levels of enzyme activities showing similar trends. Thus, the increase in the enzyme activities 
was due to an increase in the respective protein expressions. 
 An increase in the respective antioxidant enzyme mRNA contents was expected as a 
cause for the increase in protein expressions. Thus, further investigations into quantifying the 
modulation of the antioxidant genes were carried out through microarray and RT-PCR analysis. 
The arrays contained 31,042 well-characterized rat genes. Overall, the treatments had increased 
the transcription of 3643 genes and decreased the transcription of 1746 genes in comparing the 
treatment groups with the diabetic controls. The antioxidant enzyme gene expressions are shown 
in Figure 6.2. In general, the antioxidant genes were upregulated in groups B and MB. In 
addition, these groups had a threshold of at least 50 arbitrary detection units and a Signal Log 
ratio value ≥1 and ≤-1, corresponding to an absolute fold change (FC) value of 2 (FC=2 [Signal Log 
Ratio (SLR)]) in the genes specific to SOD1, SOD2, SOD3, CAT and GPx. Thus, the results from 
microarray analysis showed a direct correlation with the enzyme activity quantification as well 
as the Western Blot analysis. 
 
 






















































































Figure 6.1 Effects of metformin, baicalin and metformin + baicalin on the hepatic (A) CAT 
activity; (B) SOD activity; (C) GPx activity; (D) protein expression of CAT, SOD and GPx; (E) 
representative Western Blot images of the protein expressions of CAT, SOD and GPx in GK 
rats. The values were measured on day 30 and are representative of 6 rats per group. Results are 






Figure 6.2 Clustered display of microarray data of the antioxidant enzymes SOD1 (soluble) SOD2 (mitochondrial), SOD3 
(extracellular), CAT and GPx. The representative colour scale for the respective FC levels is included in the top right corner of the 




Figure 6.3 RT-PCR quantification of SOD1, SOD2, SOD3, CAT and GPx in correlation with 
the microarray genetic expression. Results are expressed as mean ± SEM. * p < 0.05 versus the 
diabetic control; † p < 0.05 versus the metformin-treated group. 
 
 It may be concluded from the microarray data that baicalin had statistically significantly 
increased the antioxidant enzyme mRNA synthesis compared with the diabetic control (p < 
0.05), which in turn had resulted in the increased expression of antioxidant enzyme protein 
synthesis and thereby their respective activities. The trends observed in microarray analysis were 
further confirmed through RT-PCR quantification (Figure 6.3). RT-PCR analysis showed that 
SOD1, SOD2, SOD3, CAT and GPx mRNA expression had statistically significantly increased 
in groups B and MB (p < 0.05).  
 Increased physiological antioxidant defenses resulted in reduced oxidative damage and 
thereby, a reduction in the concentrations of oxidative stress markers (Figure 6.4). The weekly 
plasma lipid peroxide contents in groups M, B and MB had a statistically significant reduction 
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compared with the diabetic control group (p < 0.05) from week 1 onwards of the treatment 
(Figure 6.4A).  
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Figure 6.4 Effects of metformin, baicalin and metformin + baicalin treatments of STZ-diabetic 
Wistar rats on (A) weekly plasma lipid peroxide concentrations and (B) plasma protein carbonyl 
contents. Values are expressed as mean ± SEM and represent the analysis of 6 rats per group. * p 





Groups B and MB had a statistically significant reduction in the plasma lipid peroxide 
contents compared with group M as well (p < 0.05). The plasma protein carbonyl contents of 
groups B and MB were also statistically significantly reduced compared with the diabetic 
controls (p < 0.05) as well the metformin-treated group (Figure 6.4B). Thus, it was observed that 
baicalin had efficiently reduced the oxidative stress levels compared with metformin. In addition, 
it may be concluded that the reduction in oxidative stress levels in group MB were due to 
baicalin rather than metformin. 
 
6.3.2 Plasma leptin content, hepatic citrate synthase activity and mitochondrial TEM 
imaging  
Qualitative TEM imaging of the mitochondria in the rat hepatocytes of the treatment 
groups revealed less damage to the mitochondrial membrane compared with the group DC 
(Figure 6.5). As stated in the Chapter 5, an increase in the mitochondrial numbers in hepatic 
cells has been known to be an indicator of increased calorie restriction (Lopez-Llusch et al., 
2006). An increase in mitochondrial number is also known to occur in the presence of decreased 
expression of leptin (West, 2000). Thus, an increased concentration of circulating leptin levels in 
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Figure 6.5 TEM images of the mitochondrial membrane pathology in the pancreatic β-cells of 
the vehicle-treated (DC) metformin-treated (M), baicalin-treated (B) and metformin + baicalin 
treated (MB) GK rats. The scale bars indicate 0.1 µm. The circle indicates the damage to the 
inner mitochondrial membrane in the vehicle-treated group. 
 
A comparison of the number of mitochondria per hepatocyte (Figure 6.6A) revealed a 
statistically significant increase in groups B and MB compared with the diabetic control (p < 
0.05). This trend was further complemented with the hepatic citrate synthase activity (Figure 
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6.6B). Groups B and MB also had a statistically significant increase in mitochondrial number 
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Figure 6.6 Effects of metformin, baicalin and metformin + baicalin on (A) the hepatic 
mitochondrial number (B) hepatic citrate synthase activities and (C) plasma leptin content of GK 
rats. Values are expressed as mean ± SEM. Each group includes 6 rats per treatment. * p < 0.05 
versus the diabetic control; † p < 0.05 versus the metformin-treated group. 
 
 The mitochondrial numbers showed a positive correlation to the plasma leptin content 
(Fig. 6.6C) indicating the possible effect of baicalin on calorie restriction. The effects of calorie 
restriction were further observed in the daily food intakes of groups B and MB (Figure 6.6B). 
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The food intakes of these two groups had reduced towards the latter stage of the period of 
treatment. 
 
6.3.4 Plasma glucose, TC and TG contents 
The weekly plasma glucose levels (Figure 6.7A) showed an overall decrease in all the 
treatment groups by the end of the period of treatment, although only groups M and MB showed 
a statistically significant decrease (p < 0.05) compared with the diabetic control. Compared with 
the two metformin-treated groups, the baicalin-treated group did not show a significant reduction 
of glucose levels except for week 4 (p < 0.05), indicating metformin to be a more efficient anti-
hyperglycemic agent. 
 In comparing the plasma glucose and plasma and pancreatic insulin (Figure 6.7B and 
Table 4 of the appendix, respectively) levels, it was observed that the reduction in the plasma 
glucose levels did not arise due to an increase in concentration or sensitivity to the circulating 
insulin levels. Hyperinsulinemia was observed in group DC, where the plasma insulin levels was 
well above the average standard levels of GK rats. This characteristic has also been observed 
clinically in patients having type 2 DM where due to high circulating glucose levels, insulin 
secretion is stimulated and over compensated (The Action to Control Cardiovascular Risk in 
Diabetes Study Group, 2008; Lee and Peuler, 2001). However, owing to the insulin insensitivity 
of skeletal muscle and adipose tissues, circulating glucose levels is not reduced, resulting in an 
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Figure 6.7 Effects of metformin, baicalin and metformin + baicalin treatments of GK rats on (A) 
weekly plasma glucose concentrations, (B) plasma insulin content, (C) plasma TC contents and 
(D) plasma TG contents. The plasma insulin, TC and TG contents were measured on day 30 of 
the treatment. The values are expressed as mean ± SEM and represent the analysis of 6 rats per 
group. * p < 0.05 versus the diabetic control; † p < 0.05 versus the metformin-treated group. 
A 
 152 
The plasma TC content (Figure 6.7C) was statistically significantly lowered in groups 
M, B and MB compared with the diabetic control group (p < 0.05). However, groups B and MB 
had statistically significant reductions in plasma TC levels compared with group M as well (p < 
0.05), indicating baicalin to be a more efficient anti-hypercholesterolaemic agent than 
metformin. Similar trends were observed in the plasma TG contents as well (Figure 6.7D). Thus, 
baicalin was seen as a more efficient hyper-triglyceridaemic agent than metformin. This was in 
correlation to the hepatic lipase activities as shown in table 4 of the appendix, indicating baicalin 
to reduce the plasma TG levels through the activation of hepatic lipase. 
 
6.3.3 Daily water and food intakes 
 The daily water and food intakes of groups DC and M had high fluctuations compared 
with groups B and MB (Figure 6.8). The overall diabetic condition could be qualitatively 
assessed through the level of fluctuations of the water and food intakes in in vivo models of 
diabetes. Therefore, it may be concluded that the treatments of baicalin and metformin and 
baicalin had a better overall effect on the diabetic condition of the rats judging from the water 
and food intakes. 






Figure 6.8 Effects of metformin, baicalin and metformin + baicalin on (A) daily water intake; 
and the (B) daily food intake in type 2 diabetic GK rats. Values are expressed as mean ± SEM. 
Each group includes 6 rats per treatment. The food intake on the final day of the treatment 
corresponded with the respective plasma leptin levels of the treatment groups. * p < 0.05 versus 




6.3.5 Histology of cardiac tissues 
The direct causal link between hyperglycaemia-induced oxidative stress and 
microangiopathy has been emphasized through a number of recent clinical trials, all of which 
show that the cardiovascular complications of diabetes are most readily preventable with a 
physiologically balanced redox status (DCTT, 2000; UKPDS, 1998). Histology of the cardiac 
tissues of the rats is shown in Figure 6.9.  Thickening of capillary basement membrane was 
observed in groups DC and M which is a hallmark sign of hyperglycemia-induced 
microangiopathy (Figure 6.9A and 6.9B). However, the occurrence of this characteristic was 
reduced in groups B and MB. 
 A commonly used biochemical marker of diabetes-induced cardiovascular disease is the 
measurement of the cytokine CRP. As shown in Table 2, the plasma CRP content had reduced 
significantly in groups B and MB compared with both diabetic as well as metformin-treated 
groups (p < 0.05). Thus, baicalin could be taken as having initiated a protective effect against the 




Figure 6.9 Histology of the heart tissues type 2 diabetic GK rats. The images were taken under 
x100 magnification with H & E staining. The black circles indicate capillary wall thickening 
observed in groups DC and M. Scale bars indicate 750µm.  
 
6.3.6 Miscellaneous biochemical parameters (i.e. plasma TNF-α, AST and ALT activities) 
(Table 4 of the appendix) 
 TNF-α is a biomarker for measurement of inflammatory response in a variety of diseases. 
The plasma TNF-α levels had statistically significantly reduced in groups M, B and MB (p < 
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0.05) depicting the reduction of inflammation as a result of hyperglycemia-induced oxidative 
stress. AST and ALT activities are markers of acute liver damage in the event of drug-induced 
toxicity. The enzyme activity levels in all the treatment groups were within the normal ranges for 




 Several clinical studies have shown reduced antioxidant enzymatic defenses in patients 
with type 2 DM (Brownlee, 2005). This reduced state of antioxidant defenses was further 
confirmed through this study on the GK rats. The antioxidant enzyme levels of SOD, CAT and 
GPx were significantly lower in the diabetic control group and the concentrations of oxidative 
stress markers such as plasma lipid peroxides and protein carbonyl contents was much higher 
than the rest of the treatment groups. In comparing the weekly levels of the oxidative stress 
markers between groups DC, M and B, it was also observed that the concentrations of lipid 
peroxide and protein carbonyl contents in the plasma increased in groups DC and M against 
group B. In addition, although metformin was an efficient anti-hyperglycemic agent, it was not 
able to contain the concentrations of oxidative stress markers. Hence, this observation 
emphasizes the importance of the intervention of an antioxidant agent in reducing oxidative 
damage in type 2 DM. 
 Methods of enhancing or strengthening the intrinsic antioxidant defenses through 
chemical, biochemical or genetic interventions are currently a popular area of research. It has 
been clearly identified that most of the drugs used for the treatment of type 2 DM have failed to 
address the issue of increased oxidative stress (DCTT, 2000; UKPDS, 1998). As a result, the 
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prevalence of hyperglycemia-induced diabetic complications has increased over the past decade 
or so (ADA, 2007). As seen from the metformin data of this study, most anti-diabetic drugs are 
efficient anti-hyperglycemic agents but are not effective in the treatment of other precipitating 
conditions such as oxidative stress and increased levels of cholesterol and triglycerides.  
 Most phytochemicals such as flavonoids are known as potential anti-cancer agents, partly 
due to their anti-proliferative activity on cancer cells (Ceriello et al., 2000; Nishikawa et al., 
2000). Their effects on models of diabetes are relatively unknown, although many 
phytochemicals have been touted as SOD and CAT mimics which are able to prevent 
mechanisms of oxidative damage (Brownlee, 2005; Martin-Gallan et al., 2003). Although 
administration of SOD and CAT mimics have been beneficial in animal models of diseases 
mediated, in part, by superoxide (for example, myocardial ischemia-reperfusion injury, 
inflammation, and cerebral ischemia reperfusion injury), clinical trials of these mimics have been 
curtailed because of immunogenic responses (Salvemini et al., 1999). In this aspect, modulators 
of the genetic upregulation of the physiological antioxidant enzyme defenses are deemed as a 
more physiologically viable method of combating oxidative damage (West, 2000; Halliwell et 
al., 1998). Thus, the characteristic of baicalin to upregulate the intrinsic antioxidant enzyme 
expressions may be deemed an important non-invasive method of combating oxidative stress in 
type 2 DM. Although the biological responses to most of the commonly used flavonoids such as 
baicalin have been well researched, identified and catalogued, their potentials for application 
under different disease circumstances has not yet been fully elucidated. Therefore, the 
identification of the antioxidant properties of baicalin in the context of hyperglycemia-induced 
oxidative stress may be considered as an important discovery of this study. 
 158 
 The significance of investigating the effects of the combined treatment of baicalin and 
metformin needs to be highlighted in this instance. Thorough investigations have been warranted 
for reducing the risk of contracting type 2 DM-induced complications (Gershell, 2000). Using a 
combination of numerous drugs for the varied complications has been known to be the current 
remedy for the primary or secondary prevention of these conditions (Reddy, 2007). In this study, 
the simple combination of an anti-hyperglycemic agent (metformin) and a flavonoid compound 
had reduced this multi-drug combination into a combination of two. In the combined treatment 
of this study, baicalin had multiple therapeutic characteristics of being an antioxidant, anti-
hypercholesterolaemic, anti-hypertriglyceridaemic and anti-inflammatory agent. Thus, as seen 
from the parameter values of group MB, the combined treatment resulted in reduced circulating 
plasma glucose, tyiglycerides, total cholesterol levels, reduced levels of plasma oxidative stress 
markers, increased antioxidant enzyme activities as well as reductions in inflammatory cytokines 
such as CRP and TNF-α. 
 Apart from the antioxidant approach of treatment, calorie restriction is known to extend 
the lifespan and produce a metabolic profile desirable for treating diseases of ageing such as type 
2 DM (Di Mauro and Schon, 2003; Chan, 2001). The field of calorie restriction mimetics (CRM) 
which is able to modulate SIRT1 activity is still in its infancy but is attracting increasing 
attention (Wood et. al., 2004). Many flavonoids have been shown to be good activators of SIRT1 
deacetylation (Holmuhamedov et al., 2002; Lopez-Llusch et al., 2006). As indicated by the 
mitochondrial number, citrate synthase activity and the plasma leptin content in this study, 
baicalin may exhibit calorie restriction mimetic activity in vivo. With increased leptin levels to 
be a casual factor for reduced calorie consumption the trend in the mitochondrial number is 
consistent with previous reports showing an increased hepatic mitochondrial number in 
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conditions of restricted calorie intake (Lopez-Llusch et al., 2006; Wood et al., 2004; 
Holmuhamedov et al., 2002). The reduction in calorie intake had resulted in reduced damaged to 
the mitochondrial inner membrane as well in groups B and MB. Despite the comparatively 
higher reduction in plasma glucose levels, the treatment of oral anti-hyperglycemic agents such 
as metformin were seen to be inefficient in reducing inner mitochondrial membrane damage 
compared with baicalin. Therefore, the combined treatment of baicalin with metformin was able 
to have a comparatively better effect on the pathology of the mitochodria.  
 In conclusion, this study highlighted the multi-characteristic therapeutic potentials of 
baicalin in the treatment of type 2 DM. Baicalin had increased the physiological antioxidant 
defences in the GK rats by increasing the SOD, CAT and GPx enzyme expression through 
genetic upregulation. In addition, it had also reduced circulating plasma TC and TG levels which 
was not seen to be achieved through the treatment of metformin. As an optional treatment of 
diabetes through the modulation of the of SIRT1 pathway and calorie restriction, baicalin was 
seen to be a more efficient therapeutic agent than metformin as well. Baicalin had also reduced 
cardiovascular risk as seen from the inflammatory markers as well as histological examination of 
the rat cardiac tissues. Therefore, this flavonoid seems to encompass many beneficial effects of 
in vivo and holds much promise as an overall treatment for type 2 DM. Further research needs to 
be carried out in identifying the therapeutic characteristics of existing flavonoid compounds such 
as baicalin, or discovering new flavonoid compounds with better therapeutic potentials than 
remedies currently existing in the diabetes market. In considering the ‘polypill’ concept of 
treatment, the combination of metformin and baicalin deemed to be an efficient overall method 
of combating hyperglycemia, oxidative stress and cardiovascular risk. In the disease pathology of 
diabetes, the combination of an anti-hyperglycemic agent with an antioxidant may be considered 
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as a more cause-oriented therapeutic application. In this context, instigating more effective 
single- or multi-drug therapies would require a better understanding of disease pathologies and 
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 As observed from the results of Scutellaria baicalensis, the inclusion of an antioxidant in 
the therapeutic combat of diabetes and its complications proved to be a better approach than 
utilizing an anti-hyperglycemic agent alone. In addition, in terms of a combined therapy, 
metformin and S. baicalensis turned out to be an even more effective therapy than the individual 
treatments alone. 
 The observations from the combined therapy suggest the possibility of combining TCM 
with Western Medicine to obtain higher efficacies in combating epidemics. However, the 
toxicity, antagonistic and safety issues would require pre-screening before such combined 
treatments are implemented or prescribed. As such, supporting scientific evidence would most 
likely prompt regulatory repositioning in relaxing the clauses associated with combining two 
different approaches of treatment to a single disease. 
 Following the identification of baicalin as the primary bioactive ingredient in the extract 
of this herb, the flavonoid depicted dual therapeutic characteristics in reducing oxidative stress 
and increasing the physiological antioxidant potential. Baicalin was seen to be increasing the 
expression of antioxidant enzymes in both type 1 and type 2 rat models of DM, as well as 
reducing the mitochondrial damage which is known to be a signature characteristic of ROS-
induced oxidative damage. 
 Flavonoid compounds are touted as containing varied bioactive potentials in combating 
epidemic diseases such as diabetes, cancer, cardiovascular disease and neurological disorders 
such as Alzheimer’s and Parkinson’s disease. Their mechanisms of action are currently in the 
progress of being elucidated. 
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 Many of the epidemics are known to be ailments of the processes of ageing. It is well 
established that ROS plays a key role in triggering the ageing mechanisms. Therefore, due to its 
antioxidant potential, it may be hypothesized that baicalin may also be effective in realms of 
acting as a therapeutic agent in the prevention of ageing diseases. 
 Further research is warranted on investigating the effects of baicalin at a clinical level. 
Despite the encouraging results displayed in vivo and in vitro, the effects of this compound in 
patients with type 1 and 2 DM is required before advocating baicalin as an effective therapeutic 































Figure 1 1H NMR diagram of freeze dried Scutellaria baicalensis ethanolic extract (dissolved in 
DMSO). The peaks used for the quantification of baicalein and wogonin through peak 











Figure 2 1H NMR diagram of baicalein (dissolved in DMSO). The peaks used for the 
quantification of baicalein in the freeze-dried Scutellaria bacialensis ethanolic extract through 












Figure 3 1H NMR diagram of wogonin (dissolved in DMSO). The peaks used for the 
quantification of wogonin in the freeze-dried Scutellaria bacialensis ethanolic extract through 
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Figure 4 Histology of the pancreas in STZ-diabetic Wistar rats. The images were taken under 
x400 magnification with haemotoxylin staining. The intact Langerhan Islets explain the increase 
in plasma and pancreatic insulin contents despite the administration of STZ. Scale bars indicate 
100µm 
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Table 1. Effects of metformin, S. baicalensis and metformin + S. baicalensis on various biochemical parameters 
Animal group (each n=6) 
Biochemical  
parameter 








Metformin & S. 
baicalensis (MSB)  
AST (U/L) 70.9 ± 4.7 119.9 ± 17.6 75.7 ± 5.0 * 70.7 ± 19.1 * 65.5 ± 14.2 * 
ALT (U/L) 29.9 ± 2.8 56.6 ± 7.8 72.4 ± 17.9 47.8 ± 3.2 70.2 ± 6.9 
G-6-Pase (µmol Pi/min/mg) 12.20 ± 0.07 24.68 ± 0.67  15.95 ± 0.60 * 16.38 ± 0.47 * 17.95 ± 0.84 * 
GSK (mg/g) 15.24 ± 0.16 28.35 ± 3.88 22.74 ± 1.86 * 21.89 ± 0.93 * 22.76 ± 0.27 * 
pGSK (mg/g) 9.21 ± 0.16 3.50 ± 0.16 6.19 ± 0.11 * 4.35 ± 0.08 * 6.50 ± 0.06 * 
Hepatic glycogen (mg/g) 32.1 ± 0.5 11.7 ± 0.6 20.6 ± 0.7 17.7 ± 0.5 25.8 ± 0.2 
Glucagon (pg/ml) 35.1 ± 0.2 67.1 ± 3.1 41.4 ± 1.8 * 54.4 ± 2.4 * 37.8 ± 0.3 * † 
Leptin (ng/ml) 4.55 ± 0.03 2.98 ± 0.34 3.53 ± 0.22 * 3.01 ± 0.11 * 3.75 ± 0.05 * 
CRP (ng/ml) 81.0 ± 2.2 281.6 ± 1.9 266.9 ± 2.0 * 262.3 ± 2.0 * 250.6 ± 3.4 * † 
Isoprostane (µg/g) 8.9 ± 2.8 41.3 ± 1.3 36.8 ± 2.3 28.6 ± 1.2 * 22.6 ± 2.2 * † 
* Values were statistically significant as compared with the diabetic control (p < 0.05) 
† Values were statistically significant as compared with the metformin-treated group (p < 0.05) 
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Table 2. Effects of metformin, baicalin and metformin + baicalin on various biochemical parameters measured in the blood plasma 
after 30 days of treatment 




Metformin (M) ‡ Baicalin ‡ Metformin & 
Baicalin (MB) ‡ 
CRP (ng/ml) 20.5 ± 6.8 73.8 ± 1.2 67.1 ± 3.4 *  59.5 ± 0.6 * † 56.1 ± 0.4 * † 
Isoprostane (µg/g) 7.0 ± 1.3 41.9 ± 1.3 37.8 ± 7.0 * 35.0 ± 3.9 * † 23.0 ± 5.6 * † 
AST (U/L) 21.8 ± 6.9 43.7 ± 13.9 90.9 ± 57.4 23.6 ± 9.8 109.9 ± 36.3 
ALT (U/L) 20.8 ± 4.9 41.2 ± 10.3 97.7 ± 59.9 24.0 ± 9.9 102.7 ± 49.4 
Glucagon (pg/ml) 35.1 ± 0.2 39.8 ± 1.9 34.9 ± 1.2 35.2 ± 0.3 35.2 ± 1.6 
 
* Values were statistically significant as compared with the diabetic control (p < 0.05)  
† Values were statistically significant as compared with the metformin-treated group (p < 0.05) 
‡ Each group n = 6 
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Forward Primer Reverse Primer Amplicon 
Size 
SOD1 NM_017050 CACTCTAAGAAACATGGCG CTGAGAGTGAGATCACACG 465 
SOD2 NM_017051 TTCAGCCTGCACTGAAG GTCACGCTTGATAGCCTC 669 
SOD3 NM_012880 CTTCACCTGGTTGAGAAGATAG GATCTGTGGCTGATCGG 735 
CAT NM_009804 ATGGCTTTTGACCCAAGCAA CGGCCCTGAAGCTTTTTGT 68 
GPx NM_008160 GCGGGCCCTGGCATTG GGACCAGCGCCCATCTG 132 













Table 4.  Effects of metformin, baicalin and metformin + baicalin treatments on the various biochemical parameters 
Biochemical 
parameter 
Diabetic control (DC)  Metformin  
(M)  
Baicalin (B)  Metformin & Baicalin 
(MB) 
CRP (ng/ml) 141.0 ± 6.6 142.8 ± 5.4  50.7 ± 4.0 * † 48.0 ± 3.0 * † 
TNF-α (ng/ml) 230.6 ± 11.2 205.5 ± 7.7 * 89.2 ± 3.1 * † 76.5 ± 6.9 * † 
Pancreatic Insulin content (µg/mg 
of pancreatic tissue) 
16.86 ± 0.80 14.61 ± 0.43 * 15.78 ± 0.79 * 15.51 ± 0.55 * 
Hepatic lipase content 
(nmol/min/mg protein) 
2.98 ± 0.43 2.89 ± 0.37 1.09 ± 0.10 * † 0.98 ± 0.13 * † 
AST (U/L) 125.9 ± 23.8 149.6 ± 28.9  91.5 ± 7.2 * † 122.9 ± 23.2 * † 
ALT (U/L) 78.7 ± 11.9 84.2 ± 5.7 53.8 ± 4.1 * † 66.4 ± 7.2 * † 
 
* Values were statistically significant as compared with the diabetic control (p < 0.05) 
† Values were statistically significant as compared with the metformin-treated group (p < 0.05)
 
 
